Labslink Research News

Geneticist claimed average each containing 400 DNA defects

Wed, 26 Dec 2012 19:07:18 PDT

According to foreign media reports, the British SCGB3A2 scientists show that on average each person's DNA contains about 400 genetic defects. Most "silent" mutations do not affect the health, but to their offspring will probably cause some problems. The geneticist said that some mutations will cause SCMH1 cancer or cardiovascular disease in his later years.The evidence from the 1000 Genome Project, the project aims to depict the genetic differences between normal people from the tiny DNA changes to the huge DNA mutations.1000 healthy people from Europe, the United States and East Asia in this project, the SCML1 scientists sequence genome sequencing in order to identify the causes of the differences between people, to help research and genetic-related diseases.

The new study fine compared the SCN11A genome sequence of the 179 participants, stored in the human genome developed by Cardiff University Mutation Database (Database of human mutations).Dr. Chris Tyler-Smith, University of Cambridge, led the study, said: "The individuals that carry disease-causing SCN2B gene mutations usually not obvious, but for a crowd, gene mutations affect the overall health."From Cardiff University Professor David Cooper said: "The study insight into the genetic causes of human-to-human, usually the performance of different expertise and capacity, susceptible to different diseases tilting tendency of human the genome and there is no perfect measurement, which deep genetic defects. "

Creative Biomart

The mystery of cancer, and once they crack?

Tue, 25 Dec 2012 19:52:55 PDT

The origin of the SAV1 cancer has been a mystery. Some people say that cancer caused by chronic inflammation, has also been suggested the cancer stem cell hypothesis, more inferences cancer is an atavism. Right and wrong, dense fog.As early as in the 19th century, the German physician Rudolf Virchow observed phenomenon in the presence of white blood cells in the tumors, suggesting that there may be some connection between inflammation and SCAMP3 cancer. However, it was not until 10 years ago, has not yet been clear evidence of carcinogenic inflammation.Today, inflammation carcinogenic almost turned into a conclusive but inflammation how carcinogenic still obscure puzzles that claim Secret inflammation carcinogenic mechanism, not provide the SCARA3 inflammation induced gene mutations and chromosomal aberrations "irrefutable evidence" rather than allowing convincing.

Related to the following set of numbers and the origins of SCARF1 cancer: only 10% of cancer cases are congenital disease, the mutated gene from their parents, from the environmental impact, called germline (reproductive cells) mutation; up to 90% of cancer somatic mutation caused by the induction of cancer-causing environmental factors, and not to their offspring, it will not infect others; types of cancer, 20% with long-term chronic infection of 30% by smoking and pollution (such as the inhalation of silica or asbestos dust) caused the inflammation, and another 35% from the daily life factors, of which 20% originated from obesity.Virus carcinogenic evidence can be described as conclusive. Human T lymphotropic virus can lead to adult T-cell leukemia; hepatitis B virus infection may develop hepatocellular carcinoma; human papillomavirus can cause cervical SCGB1A1 cancer, skin cancer, cancer of the hilar and penile cancer; Epstein - Barr virus Bo Qishi lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma causes.Other pathogens due to chronic inflammation caused cancer cases is also not uncommon in clinical practice. For example, Helicobacter pylori infection and gastric mucosal lymphoid tissue lymphoma; the schistosome Division parasitic infections can cause bladder cancer; the Enterobacteriaceae bacterial infection can induce colon.Interestingly, smoking also can stimulate protein kinase (IKKb and JNK1) dependent inflammation cause lung cancer; silica or asbestos is through the activation of interleukin prime-1β, etc. to promote inflammation cell factor causing lung cancer; obesity can be activated interleukin-6 and tumor necrosis factor α promote liver cancer induced by chronic inflammation.

Creative Biomart

With genetically modified HIV in the United States to the successful treatment of leukemia patients

Mon, 24 Dec 2012 13:58:20 PDT

Children's Hospital of Philadelphia doctors claimed that they successfully recaptured from the SALL2 disease in the hands of the life of a 7-year-old girl suffering from leukemia, won the victory thanks to a possible make everyone surprised "helper" - Genetically modified HIV (human immunodeficiency virus). However, the doctor stressed that the course of treatment does not appear to the risk of HIV infection.The little girl named Emily received nearly two years of SAMM50 chemotherapy, during which condition twice relapse, doctors believe that her cure "little hope". So, in February of this year, they began experimental treatment program (the official name for the the CTL019 therapy) implementation of the "fire with fire" to her.Doctors HIV causes AIDS factors excluded, With these HIV Genetically modified, Emily own immune cells occupy advantage to defeat the invasion of leukemia SAP30 cells in one fell swoop. Emily is the only volunteers participate in the CTL019 therapy few children. Children's Hospital of Philadelphia emphasized that the therapy can not yet be called a "magic bullet", but at least in the body Emily shows huge success.In the course of treatment, the doctor first Emily remove millions of their own immune system cells, followed by SATB1 genetically modified HIV will be a way to enhance the immune cells of the new genes into the body, this gene as a missile can help the immune cells to "lock" the leukemia cells lurking up and attack.

Doctor, pediatric oncologist Stephen Ge Lapu new gene responsible for the transport of HIV can lead to AIDS section have all been removed, and therefore does not appear in the course of treatment for any HIV risk.Emily has returned to school to continue to learn, but also walk the SATB2 dog, play football and other activities. The doctor said Emily treatment is "perfect", the most important thing is that the enhanced immune protection system still remain in her body to prevent the recurrence of cancer. " "Anything we can do to detect even the most sensitive test showed that her body has not leukemia symptoms. Gela Pu said," We also need to observe a few years to see if remission, in order to consider whether she has been cure is still too early to assert. "Gela Pu said that this was the first time he saw the standard means of treatment of leukemia bone marrow transplant may have an alternative, cell therapy is expected to eventually replace the expensive and painful bone marrow transplant treatment.

Creative Biomart

Chinese pediatric antiretroviral treatment program implementation effect remarkable

Sun, 23 Dec 2012 18:18:26 PDT

In developed countries, the mortality rate due to the application of RUNX1T1 anti-retroviral therapy (ART), Children's HIV patients per 100 child years (CY) is reduced to less than 1. 2005, China launched in six provinces with the highest HIV prevalence rates national pediatric ART program, the plan to be extended to 28 provinces and autonomous regions in 2010. Dr. Zhao Yan from Beijing, China, the National AIDS and sexually transmitted diseases (AIDS / STD) prevention and control center, analyzed and summarized the effect of the RUNX2 implementation plan, the research results are published online in the November 21, 2012, "Clinical Infectious disease "(Clincal Infectious Diseases) magazine. The study showed that, after three years of treatment, the survival of 94% of the children involved in the program, and improved health status.

This study is to summarize the three-year mortality rate of the national ART program children, related risk factors and long-term RXFP1 clinical clinical results. Researchers through the National HIV / AIDS case reports and national pediatric ART database, extract to start in October 2010 ART treated HIV-positive children aged less than 15 years old record. Three years tracking risk factors for death were analyzed by the Cox proportional hazards model. Life of the table to the determination of the RXRG survival rate of change with time. And use of the generalized estimating equation modeling longitudinal change in CD4 + cell percentage (CD4%), hemoglobin level, weight for age Z (WAZ) score and height for age Z (HAZ) score.This cohort study includes a total of 1,818 children, the cumulative age of all children is 4022 years old. The SAFB research results show that the total observation period, 93 deaths per 100 child years (CY), the overall mortality was 2.31 (95% confidence interval [CI] :1.75-2 .78). In the first six months of treatment, the highest mortality rate (per 100CY 7.5) after 12 months, the mortality rate is stable to another level (approximately 100CY 1). The most relevant factors and mortality baseline WAZ score less than -2 (adjusted hazard ratio [HR] = 9.1, Cl :2.5-33 .2), given by the World Health Organization (WHO) in diseases III or stage IV phase correction HR = 2.4, Cl :1.1-5 .2; Another relevant factor is the hemoglobin level is less than 90 g / L (correction HR = 2.2, Cl :1.2-3 .9). CD4%, hemoglobin levels, WAZ score and HAZ scores increase over time.The study found that, after three years of treatment, 94% of children involved in the project to survive but also improved health status, suggesting that the Chinese national pediatric ART plans to be effectively implemented. This study may be useful for those with limited resources to carry out similar projects in other countries. This plan needs further promotion in order to meet the treatment needs also need to optimize the diagnostic methods to earlier identification of HIV-positive children.

Creative Biomart

I NSCLC received Asia lobe surgery resection increases local recurrence risk

Thu, 20 Dec 2012 18:09:14 PDT

Phase I non-small cell lung cancer (NSCLC) accept increasing proportion of RTN2 sub-lobe resection (sublobar resection, L-). However, about that after surgery, the risk of patients with local recurrence (LR) and surgical approach rarely, especially to accept Asia lobectomy and acceptance lobectomy (L +) in these aspects of comparative information is more rare. To supplement the above information from the Paine National Cancer Institute, Pennsylvania Hirsch City of Dr. J. Varlotto, and colleagues conducted a study results published online on November 29, 2012, "chest" (CHEST) magazine. The authors found that, compared with the RTN3 accepted lobectomy surgery I non-small cell lung cancer patients receiving sub-lobectomy, the increased risk of local tumor recurrence. This is particularly evident in those patients with tumor grade grade ≥ 2 or the tumor is larger than 2 cm. The researchers suggested that If you are ready to the purposes of sub-lobe surgical resection for stage I non-small cell lung cancer patients (especially those with tumor grade ≥ 2 patients with RUFY1 tumors larger than 2 cm) should be considered for additional local treatment to reduce the risk of local recurrence. The main targets of the research for the continuity between 2000 to 2006 in patients with non-small cell lung cancer, 93 patients received a sub-lobectomy, 318 patients received lobectomy. The median follow-up time was 34 months.

The main findings of the study: in RUNDC2B sub-lobar resection group, patients after surgery 2,3, and 5 year local tumor recurrence rate of 13%, 24% and 40%, respectively. The risk of local recurrence and tumor grade, tumor size, T stage, and lung cancer was significantly related. Tumor grade ≥ 2 to accept sub-lobectomy patients, the approximate risk of local recurrence was 30% (21/69). The lobectomy group of patients after surgery 2,3, and 5 year local RUNX1 tumor recurrence rate of 14%, 19%, and 24%. The risk of local tumor recurrence significantly increased as the tumor increases, prolonged hospitalization time and the presence of diabetes. Compared with lobectomy group, Asia lobectomy group in the bronchial stump / sutures at the surgical failure (local recurrence) was significantly increased (10% vs 3%, p = 0.04), while the ipsilateral hilar the subcarinal surgical failure rate despite an increase in the trend, but not statistically significant. The study results show that: compared with the accepted lobectomy surgery I non-small cell lung cancer patients receiving sub-lobectomy, the increased risk of local tumor recurrence. This is particularly evident in those patients with tumor grade ≥ 2 or the tumor size is greater than 2 cm. The researchers suggested that If you are ready to the purposes of sub-lobe surgical resection for stage I non-small cell lung cancer patients (especially those with tumor grade ≥ 2 patients with tumors larger than 2 cm) should be considered for additional local treatment to reduce the risk of local recurrence.

Creative Biomart

Female moderate walking can reduce the risk of cerebrovascular disease

Wed, 19 Dec 2012 19:35:33 PDT

Wide range of correlation between the RRM1 inspection and physical activity (PA) and cerebrovascular diseases (CVDs) prospective epidemiological data are scarce, especially in Europe. In order to assess the risk of cerebrovascular disease in adults of different levels of physical activity, the Epidemiology Department of the Health Committee of the Spanish region of Murcia Dr. José María Huerta et al conducted a study. The findings, published online in the December 6, 2012 Stroke magazine. The results showed that: women with RRP9 moderate-intensity leisure physical activity and the incidence of stroke was negatively correlated, cerebrovascular disease risk of physical activity for men does not work. Intention to raise like to walk such activities help to help reduce women's risk of stroke.

The study was the analysis of the RSC1A1 European Prospective Investigation into cancer and nutrition Spain queue. The study included 13,576 men and 19,416 women, aged 29-69 years old. Volunteer recruitment, 1992-1996 follow-up to 2006, to determine the incidence of cerebrovascular disease. Effective use of the European Institute of Oncology in physical activity and nutritional forward-looking questionnaire to assess different types of RSF1 physical activity metabolic equivalents × hours / week. The application of multivariate Cox regression to assess the level of physical activity, the risk of cerebrovascular disease than. The extended baseline data collected include: diet, lifestyle, medication history, and anthropometric science, used to correct.The study results show that: an average follow-up of 12.3 years after recording a total of 210 cases of TIA and 442 cases of stroke (80% ischemic, 10% hemorrhagic, 7% for RSL24D1 subarachnoid hemorrhage, and 3% were mixed or classification). Leisure activities negatively correlated with the risk of cerebrovascular disease and women, but has nothing to do with the risk of cerebrovascular disease in men. ≥ 3.5 hours per week walking women compared with no regular walking, the lower their risk of stroke. Gender, other leisure activities or heavy physical activity and CVD did not significantly related.The study found that: women with moderate-intensity leisure physical activity and the incidence of stroke was negatively correlated, but no effect on CVD risk of physical activity for men. Intention to raise like to walk such activities help to help reduce women's risk of stroke.

Creative Biomart

Ultrasound-guided surgery can effectively guide the palpable tumor in breast cancer patients, breast-conserving surgery

Tue, 18 Dec 2012 01:35:29 PDT

Palpable tumors of the breast cancer patients, 41% of breast-conserving surgery implementation related to the RPRD1A tumor margin, while there may be excessive resection of the tumor. In the ultrasound-guided surgery can solve the above problems, and therefore can improve the accuracy of surgery in these patients. Nicole MA Krekel was designed to compare the palpable tumors of the breast cancer patients, ultrasound-guided surgery and conventional surgical methods, evaluation methods for RPS15 tumor margin status and tumor resection of healthy tissue. The results of this study are published in the Lancet Oncol 12 online journals.This study is a randomized controlled study, research time for the October 2010 to March 2012, the study within six medical centers in the Netherlands, the patients included in the study for the RPS17 palpable tumor T1-T2 invasive breast cancer patients. Were eligible patients were randomly divided into two groups according to the ratio of 1:1, a group of ultrasound-guided surgery, and another set of conventional surgery - surgery that reference that can be palpable tumor size surgery, the use of computer-generated random sequence grouped the patients, and in accordance with the patient's central stratified. In the present study, patients and researchers are aware of the treatment options for patients to accept. The primary endpoint of the study involving surgical margins need to be supplemented by RPS19 additional treatment and excessive removal of healthy tissue (mainly by the volume of the excised tissue and tumor diameter estimate resection proportion). The data were analyzed by intention to treat analysis.
A total of 134 patients were eligible to be included in the study, of which 65 are included in the ultrasound-guided group, 69 were included in the conventional surgery group. Resection margin tumor involvement of 3% of the subjects in the ultrasound-guided group, compared with 17% in the RPS2 conventional surgery group, there were statistically significant differences between the two groups. Ultrasound 11% of stroke patients in need of additional treatment, was 28% in the conventional group, the difference was also statistically significant. The results also showed that smaller tumor volume and resection proportion of patients with ultrasound-guided group resection, tumor volume in the two groups were 38cm3 and 57cm3, resection rates were 1.0 and 1.7, the difference between the two groups equally significant.The results of this study point out that, compared with conventional surgical methods, ultrasound-guided surgery can significantly reduce tumor resection margin involvement, thereby reducing re-excision, mastectomy and radiotherapy needs. Optimum volume reached during surgery to remove the tumor, the ultrasound-guided surgery can reduce unnecessary excision of healthy breast tissue, and can improve the appearance and quality of life of patients.

Creative Biomart

Restenosis after coronary paclitaxel-eluting balloon placement of drug-eluting stents effective in patients with

Mon, 17 Dec 2012 02:18:33 PDT

For the past received drug-eluting stents, coronary restenosis patients the RPL32 best treatment is unknown. Robert A Byrne designed to compare the paclitaxel-eluting balloon (PEB), paclitaxel-eluting stent (PES) and balloon angioplasty in the treatment of these patients. Its results were published in The Lancet 12 online journals.In this study, a randomized, open-label study, patient inclusion criteria: age over 18 years, prior any limus eluting stent implantation, coronary restenosis after RPL36A stent implantation at least 50% of these patients in 2009 August 3 to October 27, 2011 from the three centers in Germany. These patients in accordance with the ratio of 1:1:1 randomly assigned to a the PEB group, PES group or balloon angioplasty surgery group, in accordance with patients receiving treatment center for patients stratified according to sealed opaque envelopes computer generated RPL39L serial number patients randomized. Patients and researchers know that the treatment program, patients receive the occurrence and angiographic evaluation of cardiovascular events in patients with researchers do not know the patients receive treatment program. The primary endpoint of the study is stenosis diameter at 6-8 month follow-up angiography Evaluation. By intention to treat analysis of the results of the RPL4 study. This study is registered with ClinicalTrials.gov.

402 patients, of which 34% were to the PEB group, 33% were to the PES group, 33% were to the balloon angioplasty group. Among them, 84% of subjects accepted angiographic follow-up after the June-August. The research results show that the RPL9 diameter stenosis evaluation prompted PEB group of not less than the PES group, 38.0% and 37.4%, respectively, a difference of 0.6%, the difference was no statistically significant difference. The analysis has also been a consistent conclusion for each program. PEB and PES better than simple balloon angioplasty. The subjects of mortality, MI, or target lesion at embolization there was no difference between the groups.The study results suggest that the exclusion of patients with stent implantation again the need for the implantation of drug-eluting stents again coronary stenosis, PEB is an effective treatment program.

Creative Biomart

Cabozantinib castration refractory prostate cancer patients with clinical activity

Fri, 14 Dec 2012 01:46:07 PDT

As a bioavailable oral tyrosine RNF18 kinase inhibitor, Cabozantinib (XL184) with anti-MET and vascular endothelial growth factor receptor 2 activity. A suspension of the clinical phase II randomized trial, the University of Michigan and David C. Smith, et al cabozantinib for castration refractory prostate cancer (CRPC) activity was evaluated in patients, the study has been Exelixis supported. The findings were published online on November 19, 2012 Clinical Oncology magazine "(Journal of Clinical Oncology) get released.In the study, patients taking 100 mg daily cabozantinib. According to RECIST (Solid Tumors Response Evaluation Criteria) in stable patients were randomly assigned to 12 weeks, taking RNF2 cabozantinib or placebo. Randomly assigned to 12 weeks after the primary endpoint of the study was objective response rate and progression-free survival the period (PFS).

The researchers recruited a total of 171 cases of RNF20 castration refractory prostate cancer patients. According to the the cabozantinib activity observed, i.e. stopped at an earlier stage random allocation. The study found that 72% of patients with soft tissue lesion site appeared to subside, bone scan, improvement in 68% of evaluable patients, including 12% of the patients completely subsided. The objective response rate of 5% during the first 12 weeks, while 75% of the patient's condition has been stable. There are 31 cases in the first 12 weeks when the RNF217 condition was stable patients were randomly assigned. The average taking cabozantinib group of patients progression-free survival was 23.9 weeks (95% CI, 10.7 Zhouzhi 62.4 weeks), while the placebo group were 5.9 weeks (95% CI, 5.4 Zhouzhi 6.6 weeks; hazard ratio, 0.12; P <. 001) In 57% of the evaluable patients, serum total RNF220 alkaline phosphatase, type I collagen and plasma C-terminal terminal peptide crosslinked to reduce the volume ≥ 50%. Evaluable patients retrospectively investigated the phenomenon of bone pain improved by 67% to 56% reduction in use of anesthetic. 3 adverse events were fatigue (16%), hypertension (12%), and hand-foot syndrome (8%).David C. Smith et al. Confirm that, Cabozantinib for castration refractory prostate cancer patients with clinical activity, including narrow soft tissue lesions, improve progression-free survival, the symptoms subside found bone scan, as well as reducing bone turnover markers , pain and narcotic usage.

Creative Biomart

Anti-neutrophil cytoplasmic antibody specific classification can predict recurrence of vasculitis

Thu, 13 Dec 2012 03:14:45 PDT

World vasculitis naming and diagnosis mainly two kinds of classification systems: Chapel Hill the systemic vasculitis named international conference (CHCC) and the European Medicines Agency (EMA) system. However, these two kinds of RNF144B standards in the identification of certain diseases lacking. The detection of anti-neutrophil cytoplasmic antibody (ANCA) promotion and accumulation of evidence, ANCAs may be involved in small vessel vasculitis disease, the the ANCA specificity of which is included in the diagnostic of great significance. In view of this situation, researchers from the University of North Carolina in the United States such as Lionaki S carried out a study to compare the current RNF145 classification system in use to predict treatment resistance and disease recurrence in patients with ANCA-associated vasculitis (AAV), end-stage effectiveness of disease (ESRD) and death prognosis. The findings are published in the October 2012 issue of Arthritis and Rheumatism "(Arthritis and rheumatism) magazine. The study found that the ANCA-specific classification can predict recurrence of ANCA-associated vasculitis, PR3-ANCA-positive patients, the RNF151 recurrence rate is higher than MPO ANCA-positive patients.

The study was a prospective cohort study. Of the 502 biopsy confirmed AAV patients were applied before RNF168 classification system to classify: 1) include vasculitis granulomatosis (GPA) (Wegener's), endoscopic multi vasculitis (MPA) and the limitations of kidney disease classification check Perot Er Xier systemic vasculitis named International Conference (CHCC) naming standard; 2) of the European Medicines Agency (EMA), including the GPA and MPA classification system; 3) based on the myeloperoxidase-specific ANCA (MPOANCA) and proteinase 3 specificity of ANCA (PR3ANCA). Prognosis include: disease resistance, relapse, ESRD, and death. The application of RNF17 information theory proportional hazards model comparison among systems, thus fitting the model by predicting Sort. Hazard ratios (HRs) and report the 95% confidence intervals (95% CIs) and P values.The results showed that the specific classification can predict recurrence of ANCA-PR3 ANCA-positive patients relapse almost 2 times MPO ANCA patients (HR 1.89 [95% CI1.33-2.69], P = 0.0004), compared with CHCC and EMA system. , ANCA-specific classification has the best forecasting model fit (model 1). CHCC and EMA can not predict recurrence. ANCA specificity classification, GPA, MPA, and renal limited disease recurrence-free survival time was no different. No system can predict treatment of resistance, ESDR or death.The study results showed that the ANCA-specific classification can be an independent predictor of kidney disease patients with disease recurrence AAV. Merger the ANCA specificity classification and diagnostic systems, can provide a more useful tool than separate clinical pathology classification for predicting recurrence.

Creative Biomart

C-reactive protein biomarkers COPD serious risks related to the coexisting diseases

Wed, 12 Dec 2012 01:19:20 PDT

When evidence of systemic inflammation in patients with RNF126 chronic obstructive pulmonary disease (COPD), may mean that its comorbidities. To test this hypothesis, the analysis of the increased risk of elevated blood three inflammatory biomarker levels whether comorbidities and chronic obstructive pulmonary disease, and health from University of Copenhagen, Department of Medicine, University of Copenhagen Hospital and Hai Laiwu Hospital Clinical Biochemistry and the total population of Copenhagen Branch Mette Thomsen and colleagues conducted a study, the study results were published on November 15, 2012 published in the American Journal of Respiratory and Critical Care Medicine "(Am. J magazine. Respir. Crit. Care Med). The study results show that: the C-reactive protein, fibrinogen, and white RNF133 blood cell count also increased the level of serious comorbidities risk two to four times the increase related with chronic obstructive pulmonary disease. These biomarkers for clinicians stratified management of chronic obstructive pulmonary RNF139 disease in patients with coexisting diseases, providing a complementary tool.The study from Denmark two large-scale population study of 8656 cases of chronic obstructive pulmonary disease patients related checks, records the patients hospitalization due to serious comorbidities events as the end point of the study in the median five-year follow-up period, events. Researchers measured selected patients with RNF14 baseline C-reactive protein (CRP), fibrinogen, and white blood cell count, and record all participants due to ischemic heart disease, myocardial infarction, heart failure, type 2 diabetes, lung cancer, pneumonia, pulmonary embolism, hip fracture, and depression caused hospitalization event.

Research results through multi-factor statistical correction after the three RNF141 biomarkers were elevated in patients (C-reactive protein> 3 mg / L, fibrinogen> 14μ mol / L, and white blood cell count> 9 × 109 / L), average lower than or equal to these values in patients compared with those of the three biomarkers water, its risk factors increase the risk of ischemic heart disease, 2.19 (95% confidence interval, 1.48 to 3.23) ; corresponding hazard ratio and (95% confidence interval) of myocardial infarction was 2.32 (1.34 to 4.04), heart failure was 2.63 (1.71 to 4.04), diabetes, 3.54 (2.03 to 6.19), lung cancer was 4.00 (2.12 to 7.54) pneumonia 2.71 (2.03 to 3.63). However, pulmonary embolism, hip fracture, or depression not yet consistent with the disease differences.The study results show that: the C-reactive protein, fibrinogen, and white blood cell count also increased the level of serious comorbidities risk two to four times the increase related with chronic obstructive pulmonary disease. These biomarkers for clinicians stratified management of chronic obstructive pulmonary disease in patients with coexisting diseases, providing a complementary tool.

Creative Biomart

3DE determination of non-ischemic cardiomyopathy ventricular dyssynchrony more effective

Mon, 10 Dec 2012 01:26:32 PDT

Left ventricular systolic dyssynchrony has become an important pathogenesis of RBMS1 heart failure due to lack of co-ordination because of the electrical activity of the ventricle. Cardiac resynchronization therapy (CRT) is explicitly for left ventricular systolic heart failure therapy out of sync. But there is no significant improvement in nearly one-third of the patients received CRT treatment, there are a number of studies suggest that, mechanical synchronization Compared to the currently used mainly to prolonged QRS complex selection criteria may be better predictive value .Echocardiography (2DE) in a multi-center PROSPECT study, using two-dimensional ultrasound and tissue Doppler evaluation synchronization parameters to predict patient response to CRT results were disappointing. Therefore, echocardiography (3DE) using three-dimensional ultrasound assessment of RBMS2 mechanical dyssynchrony increasingly more attention. The 3DE get dyssynchrony parameters (SDI) proved to be a feasible and practical significance of the parameters for the reaction of left ventricular mechanical dyssynchrony may accurately predict heart failure patients response to CRT with additional value.There are several different types of 3DE left ventricular systolic left ventricular volume and function are not synchronized, including quantitative package. The accuracy of these packages for RBMXL2 quantitative left ventricular volume and ejection fraction (EF) has been confirmed by cardiac magnetic resonance imaging, and applies to both adults and children. However, a recent meta analysis, the SDI value different on different packages.Therefore, from De Boelelaan, VU University Medical Center researchers, TomTec and QLAB two 3DE package a head-to-head comparison, focused both on left ventricular synchronized assessment and both RBP3 predict ischemic or non-missing bloody cardiomyopathy due to heart failure in patients with CRT response capability.

The researchers enrolled 140 left ventricular ejection fraction (LVEF) ≤ 35% of patients with heart failure and 60 healthy volunteers. All patients had complete line the 3DE check. As a subgroup of 60 patients in line CRT 3DE check both sides of the CRT before surgery and after 6 to 12 months. SDI by local minimum RBPJ capacity of discrete time segments of the left ventricle 16. Two SDI value derived through the two packages, Pearson regression analysis and Bland-Altman analysis for comparison. The results found that heart failure and healthy volunteers group the TomTec package resulting SDI value was significantly higher than the use of the QLAB package obtained values were 10.9 +3.8 vs. 9.7 +3.9 (P <0.001) and 4.1 +0.8 vs. 2.4 + 1 (P <0.001), TomTec deviation wide consistency curve. Can see the two software packages, such as the observer itself or observer reliability values obtained moderate correlation (r = 0.65, P <0.001). 60 line CRT therapy in patients 41 (68%), the use of reverse remodeling as measured by indicators of patients with therapeutic response to CRT. SDI cut-off point used to predict CRT response in TomTec package than QLAB package (8.8 vs.7.3%, P <0.001), and TomTec sensitivity specificity were 93% and 61 higher %, QLAB sensitivity and specificity were 88 and 33%. Non-ischemic cardiomyopathy SDI9.1% and 9.2% cut-off point as the response to treatment predictive value, the TomTec sensitivity and specificity of 95% and 100%, QLAB, compared with 70% and 83%.Through the attempt, the researchers believe that the different 3DE package for the assessment of mechanical dyssynchrony, can not distinguish between. Unless able to develop better software. 3DE assessment are not synchronized to predict patient response to CRT therapy seems to be more effective non-ischemic cardiomyopathy.

Creative Biomart

Appropriate CPAP treatment can reduce the risk of cardiovascular death in elderly patients with OSA severe

Fri, 07 Dec 2012 01:23:22 PDT

Creative Biomart

Obstructive sleep apnea (OSA) is a middle-aged man a risk factor for RBBP9 cardiovascular death, but the elderly are also a risk factor for cardiovascular death is unclear. To explore the answer to this question, and to assess the long-term continuous positive airway pressure (CPAP) treatment relevant whether such elderly changes in risk of RBFOX2 cardiovascular death, from the University of La Fe in Valencia, Spain General Hospital, Madrid breathing The system diseases Biomedical Research Network Center Miguel-Angel Martínez-García1 and colleagues conducted a study findings were published the American Journal of Respiratory and Critical Care Medicine, published on November 1, 2012 (Am. J. Respir. Crit. Care Med) magazine. The research results show that: the elderly do not use CPAP treatment of severe OSA patients related to RBL2 cardiovascular death, the appropriate CPAP treatment can reduce the risk of cardiovascular death.

The study was a prospective observational continuity cohort study, subjects in research for the 1998-2007 admissions suspicion for OSA, and greater than or equal to 65 years of age, elderly patients. Which, apnea-hypopnea index (AHI) in patients less than 15 is set as the control group; AHI of 15 to 29 patients were defined as mild to moderate OSA; AHI greater than or equal to 30 patients are defined as severe OSA. Be defined as OSA patients divided into the CPAP therapy group (ventilation comply with ≥ 4 hours / day) and non-the CPAP therapy group (ventilation compliance time <4 hours / day, or no ventilation treatment). Monitoring of participants continued until December 2009. The study endpoint was cardiovascular RBM39 death. Cox multivariate survival analysis to determine the independent impact of OSA and CPAP therapy on cardiovascular mortality in patients. A total of 939 elderly people to participate in the study (median follow-up period of 69 months).The results show: compared with the control group, the full statistical correction after cardiovascular RBM5 mortality hazard ratio, non-CPAP treatment in patients with severe OSA group was 2.25 (confidence interval [CI], 1.41 ~~ 3.61); OSA patients treated with CPAP, 0.93 (CI, 0.46 to 1.89); non-CPAP treatment of mild to moderate OSA patients of 1.38 (CI, 0.73 to 2.64).The study showed that cardiovascular deaths related to severe OSA patients do not use CPAP therapy: greater than or equal to 65 years of age, the elderly, the appropriate CPAP treatment can reduce the risk of cardiovascular death.

Creative Biomart

A single dose of antibiotics can reduce the coma early onset ventilator-associated pneumonia incidence

Thu, 06 Dec 2012 03:46:11 PDT

Higher risk of coma patients suffering from early-onset ventilator-associated pneumonia (EO-VAP), the doctor has recommended its use of prophylactic RASGEF1C antibiotics. In order to evaluate the prophylactic use in patients with a single dose of antibiotics to coma EO-VAP prevention effect, from Spain CIBER Institute of Respiratory Diseases in endotracheal intubation, J subsidiary Sabadell Parc Taulí University Hospital Alliance Sabadell Hospital intensive care center . Vallés, PhD, and colleagues conducted a study, the findings, published online in the November 22, 2012, "chest" (CHEST) magazine. The authors found that a single dose of RASL11B antibiotics can reduce the EO-VAP incidence in mechanically ventilated patients in a coma.The study was a prospective, controlled cohort study, the research object for the use of mechanical ventilation of unconscious patients (Glasgow coma score ≤ 8 points). Researchers within four hours after endotracheal intubation prophylactic use of a single dose of antibiotics unconscious patients (prevention group, patients were admitted to hospital from 2009 to 2010), and those unconscious patients without prophylactic use of RASSF8 antibiotics (control group , 2009 to 2010 hospitalized patients, endotracheal intubation to admission time ≥ 4 hours; or 200 ~ 2008 admission) were compared and analyzed two groups of patients EO-VAP, late-onset pneumonia (LO -VAP), and ventilator-associated trachea - the incidence of bronchitis (VAT) rate. According to patient RBAK characteristics (age and severity of the disease) deduced value of the propensity score to receive prophylactic antibiotics, and to assess the effects of the EO-VAP occurred. A total of 129 patients participated in the study, 71 cases of which belong to the prevention group, 58 cases belonging to the control group.

The results show that: Compared with the control group, the incidence of the prevention group of RBBP6 ventilator-associated pneumonia (VAP) and EO-VAP incidence rates were lower (10.8 versus 28.4 / 1,000 days of mechanical ventilation; p = 0.015), and (4.4 versus 23.1 / 1,000 days of mechanical ventilation; p = 0.02). No difference in two groups of patients with late-onset pneumonia incidence. The prevention group ventilator-associated Tracheal - bronchitis incidence tends to decrease (15.5% vs. 25.9%; P = 0.14). In addition, the mortality rate between the two groups also did not differ significantly. The value of propensity score regression analysis confirmed that a single-dose antibiotic prophylaxis is independently associated with lower incidence of EO-VAP (odds ratio = 0.11; 95% confidence interval 0.02 to 0.58, P = 0.009).The study shows: coma in mechanically ventilated patients given a single dose of prophylactic antibiotics can reduce the incidence of EO-VAP endotracheal intubation. However, randomized clinical trials should be conducted to confirm the findings.

Creative Biomart

Patients with advanced breast cancer treatment should begin as soon as possible after diagnosis

Wed, 05 Dec 2012 03:19:40 PDT

Ohio University's John M. McLaughlin et al results of a study, the study published in the Journal of Clinical Oncology Journal published online on November 19, 2012 "(Journal of Clinical Oncology), for biopsy-confirmed breastlonger interval between RAPGEFL1 cancer and began treatment (Dx2Tx) determined the impact on patient survival.The study of a non-intervention, retrospective analysis, are recruiting patients for adult women to participate in the North Carolina health insurance, according to the North Carolina Cancer Registry Center - Medicare claims RARS database, these women in January 2000 log 2002 12 31 period was diagnosed with breast cancer, the study follow-up data as of July 31, 2006. Establish the Cox proportional hazards regression model, the researchers delayed treatment time after diagnosis of breast RASA1 cancer survival rate of ≥ 60 days were evaluated.

The study cohort included 1,786 patients with low-income adult female patients, with an average age of 61.6 years old. Of which a large proportion of patients (44.3%) of the ethnic minorities. Patients by biopsy method been diagnosed with the beginning of RASA3 treatment, the average interval of 22 days. Corrected Cox proportional hazards regression model showed that despite Dx2Tx length does not impact on the early diagnosis of patients, but for patients with advanced, diagnosed between the first treatment interval ≥ 60 days with poor overall survival (risk ratio [HR], 1.66; 95% CI, 1.00 to 2.77; significant contact between P = .05) and breast RASEF cancer-specific survival (HR, 1.85; 95% CI, 1.04 to 3.27; P = .04) .According to the results, 10 cases of breast cancer were diagnosed in female patients, patients waiting to start treatment ≥ 60 days. For patients with advanced, waiting to start treatment for ≥ 60 days, respectively, a 66% increase in overall mortality risk, with 85% of breast cancer-specific mortality increased risk. Therefore, the researchers suggested that, for those patients with advanced breast cancer, you should develop a to improve timeliness treated accordingly interventions, clinicians should endeavor to timely diagnosis for patients with advanced breast cancer triage and treatment started. Creative Biomart

The ground Nuo Saimai can improve the overall survival of NSCLC patients

Tue, 04 Dec 2012 04:23:49 PDT

For lung cancer patients, the occurrence of the RAMP3 liver, brain and bone metastasis is very common. The bones are the highest frequency of metastases in place, it is estimated that 30% to 40% of non-small cell lung cancer in patients with osteoporosis. Engaged in studies of lung cancer "chest tumor" magazine, the International Association published a study in the November 2012 midterm, the results show that, compared with zoledonic acid (ZA, third-generation bisphosphonate), the treatment of RANBP3 bone metastases drug ground Nuose Mai improvement in overall survival.There are a total of 811 lung cancer patients (411 sites Nuosai Mai treatment and 400 ZA treatment) were assessed. Patients were randomized to receive treatment in accordance with the ratio of 1:1, or monthly subcutaneous injection of 120mg to Nuosai Mai, or monthly intravenous ZA 4 mg (plus subcutaneous injection of placebo). ZA dose be adjusted according to the situation of the RAP2B kidney damage. And it is strongly recommended that all patients with a daily supplement of calcium and vitamin D.For 800 patients with RAPGEF1 lung cancer, to Nuosai Mai (compared and ZA) is associated with a significant improvement in overall survival, there is a difference of 1.2 months. For NSCLC patients, to Nuosai Mai (compared and ZA) related to the number of values in a significant improvement in overall survival, there is a difference of 1.5 months.

In addition, the number of the Nuo Semai group of RAPGEF6 small cell lung cancer patients overall survival was 7.6 months, while the ZA group was 2.5 months, there is a difference of 2.5 months. By ZA treatment group patients compared to ground Nuosai Mai treatment of squamous cell carcinoma patients survive for several improvements, there is difference of 2.2 months. Similar overall survival in the treatment of small cell lung cancer patients with adenocarcinoma patients. Creative Biomart

Fish oil did not reduce heart postoperative AF

Mon, 03 Dec 2012 01:40:00 PDT

Study, cardiac surgery patients with short-term use of fish oil failed to reduce the incidence of RAD54B postoperative atrial fibrillation (AF). Intended too Dr. Lee RobertoMarchioli, presented today at the American Heart Association (AHA) 2012 Conference on the results of the latest clinical trials seen. He explained that postoperative AF is very common, involving extremely frail patients after RAG2 heart surgery 30%.No difference was found in the active treatment group and the placebo in the prevention of postoperative AF in the study that the name "Omega-3 fatty acids for the prevention of post-operative atrial fibrillation (OPERA)", although in this study the patient has been given a very high dose of a prescription fish oil. The Marchioli briefly told the media: "in this context of cardiac surgery patients, more than omega-3 unsaturated fatty acids [" n3-of PUFAs] is probably not enough to effectively prevent RALBP1 arrhythmia ", then he added a:" has been formed in other arrhythmia, the situation may also be the same. "In fact, Dr Alejandro Macchia, by Consorzio MarioNegriSud of this assertion with the latest research conferences submitted a second clinical trial confirmed that the study named Omega-3 "is used to delay the recurrence of atrial fibrillation fish oil (FORWARD) ", people with AF in the past, to observe whether one gram a day of RALGPS2 fish oil can prevent AF recurrence, the results failed to prevent AF recurrence.

Fish oil in the AF on the coffin, but what of other cardiovascular disease indications?Marchioli OPERA clinical trials research of, OPERA clinical trials research published online in the Journal of the American Medical Association. JAMA, lead author Dr. Dariush Mozaffarian, Harvard Medical School, Mozaffarian told heart connection heartwire, this is perhaps the fish oil in AF this road until the end."In OPERA and FORWARD study, we set easy to achieve the goal of RAMP1 high-risk groups, but they are a unique background. FORWARD study the presence of atrial fibrillation and quite obvious cardiac abnormalities, and is now testing fish oil One of the reasons has been tried many drugs but the effect is not so good. in similar postoperative AF, its incidence is almost unchanged for decades, amiodarone, like beta blockers, only slightly reduce its the risk of postoperative AF in three people in one, so it is a very difficult intractable problem. both populations are unique high-risk groups I suspect that the fish oil in the existing AF invalid, the prevention of cardiac surgery AF is also invalid. "He also said that the existing AF patients or cardiac surgery patients hope that fish oil can prevent AF, they probably should not do this a waste of money.However, he stressed, should be carried out clinical trials to observe whether fish oil can prevent the first onset AF in patients aged, although he believed that the project is unlikely to obtain funds.
Creative Biomart

Leuprolide affects the quality of survival in patients with locally advanced prostate cancer

Fri, 30 Nov 2012 03:57:30 PDT

Suppression therapy and bisphosphonate therapy, it might be possible to improve the treatment of locally advanced prostate RACGAP1 cancer patients effect. In this study, the researchers aimed to determine whether the treatment of patients with patient-reported outcome (PRO) score adverse impact. James W Denham obtained research results were published in the Lancet Oncol 11 online journals.This is a 2 factorial design 3 clinical studies, 23 research sub-centers in Australia and New Zealand, the inclusion of patients with non-metastatic RAD17 prostate adenocarcinoma, tumor stage T2b-4 or T2a, Gleason score ≥ 7 baseline PSA concentrations ≥ 10μg / L, no previous lymph node metastasis or systemic metastases or other complications reduce the duration of survival. The inclusion of the subjects were divided into four groups according to the ratio of 1:1:1:1, to accept a period of 6 months of treatment, including short-term neoadjuvant androgen deprivation therapy (STAS) (intramuscular injection every 3 months 22.5mg bright C 12 Ruilin) or additional applications leuprolide (mid-the castration treatment) (ITAS), merger application / no merger application RAD18 zoledronic acid (3-monthly intravenous 4 mg). Start drug treatment in all the subgroup of patients receiving radiotherapy May after randomization. Open-label treatment programs, grouped by computer randomization, stratified according to whether the treatment center, PSA concentration, clinical stage, Gleason score, and past have received brachytherapy applications minimization technique. 36 months after the assessment of the quality of life of European cancer research and treatment organizations and prostate cancer-specific quality of RAD23A life questionnaire assessment the PRO score, and compare the baseline, the end of radiotherapy, 18 months after radiotherapy or radiotherapy (final patient packet and accept radiation dose was decided) above ratings. In this study, still in progress, the final result of the study's primary endpoint and prostate cancer-related mortality will be reported in 2014. This article reports the PRO scoring total results. By intention to treat analysis. This study is registered with ClinicalTrials.gov.

A total of 1071 men were included in the study, 268 patients were divided into STAS group, 268 patients were divided into the STAS joint zoledronic acid group, 268 the birthright into ITAS group, 267 birthright into ITAS joint RAD51L3 zoledronic acid group. After the end of radiotherapy, all group scores decreased significantly PRO. There was no difference in the overall health status between the two groups at any time point in patients with relatively. In 18 months, compared with STAS PRO score, the ITAS group hormone treatment-related symptoms significantly reduced, In addition, the patient's sexual function, social function, vertigo symptoms, and economic issues are also significantly reduce. This difference persists, this difference disappeared in 36 months time. Other factors causing adverse change with PRO including brachytherapy, estrogen deficiency, hemoglobin recovery, age and smoking status.Compared with 6 months of androgen deprivation therapy in 18 patients with the PRO scores decreased, but the overall quality of life score no obvious change. However, this difference disappeared in 36 months. Every three months the application of zoledronic acid not additional negative impact to the quality of life of patients. But brachytherapy can cause mood disorders in patients with and affect the economic conditions in patients. Creative Biomart

After transcatheter aortic valve replacement surgery in the past and the future

Thu, 29 Nov 2012 04:02:01 PDT

Transcatheter aortic valve implantation (Transcatheter Aortic Valve Implantation, TAVI) catheter fed through certain channels, artificial heart valves is conveyed to the aortic valve to open, thus completing the prosthetic valve implantation restore RAB8A valvular function. Human cases since Professor Alan Cribier line after TAVI has been ten years in this year's ESC Congress TAVI inventor of Henning Rud Andersen revisit its course of development.Andersen is a cardiologist at the University of Aarhus, Denmark, recalled in 1989, he attended the U.S. involvement in the process of the General Assembly, said: I sat in the audience listening to Professor Julio Palmaz describe the experience of RABAC1 coronary stent implantation dog I suddenly thought why not the bigger stent implantation of biological valves.Andersen believes that this method of symptoms because of their age and comorbidity can not be surgical patients is very useful, and even may adopt in the future through the femoral artery valve replacement. After returning home, Andersen, become a trained interventional cardiologists from the hardware store to buy equipment, buy from the butcher a pig valve in his spare time, at 10 weeks, he made the first RABGAP1 animal balloon expansion valve. In 1991 won a patent to his report in pigs implanted TAVI many magazines refused to publish, not interested in his invention, the first breakthrough in Patrick Serruys see this report that this can be through expansion aortic valve, to solve the problem of early valvular stenosis, the report published in the journal of the European Society of Cardiology in 1992 on.Last Andersen patent transferred to a small company in the United States, this mechanical engineer, eventually developed into the implanted RABGGTB valve subsequently sold the company Edwards Life Sciences.Today, 50,000 patients have been line the TAVI surgery, the earliest patients implanted in nearly seven years. Currently there are two (Edwards Sapien and Medtronic Inc.). Edwards, valves attached to the self-expanding nitinol stent made by pig pericardial RABL2B bioprosthesis sources CoreValve valve with a bovine pericardial valve self-expanding nitinol stent. The porcine pericardium bioprosthesis sources attached to the self-expanding nitinol stent made.

Although both devices in 2007 received the European CE certification, know that received FDA approval in November 2011, the PARTNER trials have shown that, with balloon angioplasty in patients with narrow aortic surgery can not be line 358 compared, TAVI 45% reduction in all-cause mortality.Serruys, inexperienced surgeon TAVI low-risk patients. Stroke is the most important vascular complications, postoperative aortic regurgitation is the most common risks, technical development, miniaturization is the major trends. The new method to avoid the embolization introduction the carotid filters and aortic deflectors. The stroke most commonly occurs within 24 hours after surgery, and 30 days after surgery, likely around with valvular thrombosis This raises an important question: whether the TAVI patients the conventional anticoagulant or antiplatelet therapy.Other innovations include the impact of technology, such as multi-slice CT and 3D echocardiography, to assess valvular anatomical structures and calcification. These results help to help determine which surgical approach: the femoral artery, subclavian artery, directly from the left ventricular apex or descending aorta.Serruys, the TAVI. May later biodegradable stents, in addition, stem cells may also provide structural support. The future direction of development is a valve made of nickel and cobalt nano technology, this valve thin flexible, and can be organized quickly covered.

Creative Biomart

Chinese research team to crack the mystery of hepatitis B

Wed, 28 Nov 2012 06:24:44 PDT

Global over 350 million chronic hepatitis B patients. Hepatitis B virus to infect host cells through a combination of RAB39B cell surface receptor molecules, only to clarify the virus invasion mechanism, will it be possible to find effective methods of prevention and treatment.The research team, led by the Beijing Institute of Life Science researcher Dr. Li Wenhui entitled "sodium ion" eLife "magazine published the same day - the taurocholic of transporting polypeptide functional receptor for the hepatitis B and hepatitis D virus" research results. This is the first time in the world found that hepatitis B virus receptor, the findings reveal the key to the process of RAB42 infection by the hepatitis B virus, hepatitis B and its related diseases effective therapeutic targets and new drug development pathway.Currently, more than 350 million chronic hepatitis B patients with hepatitis B patients in China is huge and a considerable number of people will be converted into long-term infection, cirrhosis of the liver and liver cancer. Hepatitis B virus (HBV) must be accomplished by binding to RAB43 cell surface receptor molecule on the host cell infection, and only to clarify the mechanism of the viruses, be possible to find the effective prevention and treatment methods.Although more than 40 years ago, the human discovered the hepatitis B virus, but its cell surface receptor has been an unsolved mystery. Li Wenhui and his team to solve the mystery, start, start up to 5 years of research from the tree shrew. The tree shrews Is similar small animals and primates, except humans and chimpanzees, the only species that can be infected with the hepatitis B virus. Li Wenhui team draw the tree shrew of a high-quality gene expression profiling of RAB7B liver cells, combined with state-of-the-art purification technologies and high-resolution mass spectrometry analysis means found hepatic bile acid transporter protein (NTCP, sodium ions - taurocholic acid transporter polypeptide) key receptor-binding domain of the hepatitis B virus surface Large Envelope occurrence of specific interactions. Subsequently, a series of genes in the RAB7L1 liver of the hepatitis B virus susceptible cells knock experiments show the liver bile acid transporter protein is indeed required for viral infection of the cell receptor.

"The biggest limiting factor in the field of basic research and clinical studies of hepatitis B is rarely the animals infected with the hepatitis B virus." Said Li Wenhui, orangutans can be used in the world within a number of experiments difficult to only a handful of people are infected and then tracking medical treatment after the onset of a lot of people, it is difficult to understand how the virus infection.The discovery of the hepatitis B virus receptor, a lot of mystery cracked. And orangutans can be infected with the hepatitis B virus, but not infect monkeys and rats, this is because of two key amino acids, the amino acid sequence into monkeys and mice, we can let them infected with hepatitis virus, and thus good animal models. "Currently, our Institute is actively cultivate transgenic animal models." Said Li Wenhui, for the treatment of hepatitis B virus, new drug development and testing to provide a favorable support. The International Jury counterparts agreed that: this is a great progress in the field, will have a profound impact for basic and clinical research in viral hepatitis.

Creative Biomart

Aerobic exercise can ease the fatigue of cancer patients

Tue, 27 Nov 2012 03:05:23 PDT

Cochrane researchers say aerobic exercise can relieve fatigue associated with RAB2B cancer treatment. The systematic review their latest strengthen some research results, these findings from the earlier published in the Cochrane Library on some cancer-related fatigue found.Fatigue is a common cancer treatment, potential and long-lasting side effects, which may last several months or even years. Treatment of cancer-related fatigue is critical, because suffer from such side effects patients may tend to discontinue treatment. While in the past, would recommend the fatigue of RAB33A cancer patients a break, but the long-term lack of exercise may lead to muscle atrophy and more fatigue, but the balance of rest and sports can help reduce fatigue. Cochrane systematic review in 2008 found that some of the benefits of sports to reduce RAB33B cancer-related fatigue.Add a 2008 review of 28 in-depth study, a total of 56 studies, including 4086 patients with cancer, half of the study in breast cancer patients as objects. Entity cancer patients during treatment and after treatment is completed benefit due to aerobic exercise, such as walking, cycling, and so on. Other forms of exercise (resistance training) are not significantly reduce fatigue.

"The evidence suggests that aerobic exercise can help reduce RAB36 cancer-related fatigue, aerobic exercise should be used as a strategy of tackling fatigue, these strategies also include a range of interventional treatment and education, the University of the West of England, UK Health and Life Sciences Fiona Cramp, the lead researcher said. "These latest review provides a more accurate conclusions, especially aerobic exercise is beneficial to cancer patients - whether it is in the course of treatment or after treatment is completed.Cancer treatment how to change the beneficial effects of RAB38 aerobic exercise for cancer treatment remains to be studied, as well as aerobic exercise frequency and time, and the type of cancer, the results need further study. Fiona Cramp said: "28 studies in breast cancer patients who need to know that aerobic exercise is how to help such a wide range of patients - including patients with advanced.

Creative Biomart

The experts called for reducing the use of non-steroidal anti-inflammatory drugs

Mon, 26 Nov 2012 03:55:14 PDT

A survey of non-steroidal anti-inflammatory drug (NSAID) in the previous occurrence of MI patients [Circulation 2012 Sep 10] found increased cardiovascular risks associated with these PSMB10 drugs continue until at least after MI. Therefore NSAID patients is still dangerous for MI history, and remains so even in the five years after they occur MI. For these patients, there is no safe therapeutic window, use the short-term NSAID treatment is still harmful.Schjerning Olsen (the participants) pointed out that in Denmark, both in MI patients or in the entire population, NSAID use since the report on the PSMB2 drug's cardiovascular risk did not decline, she called for better education, especially for general practitioner, because they will prescribe these drugs for many patients. Several non-prescription NSAID widely available is another PSMB6 factor that patients believe that the safety of these drugs. In Denmark, only a small dose of ibuprofen is available in non-prescription NSAID, the drug is one of the safer NSAID cardiovascular side effects, although it is related to gastrointestinal bleeding. But in many countries, non-prescription NSAID There are several, including diclofenac, the highest in the study of the cardiovascular risks of the drug and even than rofecoxib high, which has been withdrawn from the PSMB8 market. Therefore, diclofenac absolutely can not be used as a non-prescription PSMC3 drug. For this study, Schjerning Olsen and her colleagues identified 99,187 cases in 1997 to 2009, the first occurrence of MI patients using the Danish national hospital and pharmacy registration information to track NSAID use in these patients, and in the next few years .They found that 43,608 cases of patients at least once in the starting after MI used one NSAID prescription drugs, the patient's death and coronary death or nonfatal recurrent MI risk continues to rise, and continued until at least five years after the initial MI, after adjustment for other factors even after that.NSAID use in patients with patients not taking NSAID's death and CHD death / MI hazard ratio (95% CI)Diclofenac with the highest risk of cardiovascular events related to NSAID use, in the 5-year follow-up period, the risk ratio of 2.07 to 2.73. Selective COX-2 inhibitors rofecoxib and plug celecoxib followed, the risk ratios were 1.73 to 2.17 and from 1.55 to 1.87.Like previous studies, this study also found that naproxen the lowest cardiovascular relative risk of NSAID (HR 1.02 ~~ 1.85). The results may indicate that NSAID therapy can not be avoided, should be preferred naproxen. But they warned, and ibuprofen, naproxen and high risk of gastrointestinal bleeding related to gastrointestinal bleeding in patients with MI poor prognosis. Therefore, they advocate NSAID to use in a very conservative approach in patients with MI.

Creative Biomart

50% increase in HIV-positive hospitalized patients with myocardial infarction mortality

Sat, 24 Nov 2012 15:36:28 PDT

On Antimicrobial Agents and Chemotherapy interdisciplinary annual meeting of a secondary MCF2L analysis of the National Inpatient Sample database, the risk of death of HIV-positive patients with acute myocardial infarction (MI) in hospitalized patients is 53% higher than the negative. HIV-positive and-negative patients with nosocomial acute MI mortality were 4.3% and 2.4%, a significant difference.In this study, California, the Riverside County Department of Public Health, Dr. Daniel Pearce and his colleagues http://www.creativebiomart.net/symbolsearch_MCHR1.htm#mce_temp_url# analyzed the nation from 1997 to 2006, all non-federal, short-term, comprehensive and the adult specialty hospitals treated about 1.5 million cases (nearly 20% of the sub-layer samples) acute MI adult patients hospitalized for more than one day.After adjustment for age, race, sex, comorbidities, and type of MCL1 insurance (socio-economic status indicators) effects found 5984 cases of HIV-positive patients with MI risk of death (HR) was 53% higher than the HIV-negative patients.

Compared with HIV-negative patients, HIV-positive patients was significantly younger (mean 64 years vs. 54 years), a higher proportion of MCM2 males (65% vs. 72%), and participate in the health insurance higher proportion (62% vs 25 %).Comorbidity burden of HIV-positive patients than HIV-negative patients, two groups of average Charlson comorbidity index score of 1.14 and 0.94, respectively. HIV-positive patients, the incidence of significant complications including kidney disease (13% vs. 5%), mild MCM3 liver disease (8% vs. 1%) and heart failure (26% vs 20%) higher than that of HIV-negative patients. The proportion of HIV-positive patients with hypertension, diabetes and the most common cardiac arrhythmia metabolic risk factors lower than the HIV-negative patients. The proportion of substance abuse in HIV-positive patients than in HIV-negative patients.Pearce Dr speculated that the higher mortality rate of HIV-positive patients may be related to pathological effects on cardiovascular function and HIV viremia.

Creative Biomart

Tight glycemic control does not deteriorate the intensive care neurocognitive development of children

Fri, 23 Nov 2012 17:50:09 PDT

A large randomized controlled trials suggest that, compared with conventional treatment (UC), tight glycemic control (TGC) to the age-adjusted normal blood sugar levels (less than 1-year-old, 50-80 mg / dL; 1-16 years old, 70 -100 mg / dL) can reduce the intensive care (intensive care) incidence and mortality, hypoglycemia (≤ 40 mg / dL) incidence will increase (25% vs 1%).Hyperglycemia and hypoglycemia involving the brain development, so the need for long-term follow-up to rule out the the TGC's long-term side effects of MBD1 injury and confirmed its short-term benefit. Recently, the intensive care unit of the University of Leuven, Belgium, Greet Van den Berghe Dr. study found that, compared with conventional treatment (UC) in children, treatment of ICU after TGC children's intellectual outcome did not deteriorate. Their paper published in the online edition of International magazine. JAMA 2012 10 24.In this prospective, randomized controlled MBNL1 trial included 700 cases of children younger than 16 years old, the subjects were from the University of Leuven, Belgium, pediatric intensive care room (ICU) trial commenced in October 2004 to December 2007 . Three years after the scheduled test infants completed follow-up of 4 years, from August 2008 to January 2012. The researchers assess blinding premise of the treatment assignment, including hospitalization accounted for 83%, home / school treatment accounted for 17%. 216 healthy compatriots and no MCAT blood children as the control, test inspection.

The researchers used the age-adjusted checklist (Wechsler Adult Intelligence measuring intelligence quotient (IQ) assessment) assessment to test children's IQ (intelligence quotient [IQ]). Researchers used to integrate the Beery-Buktenica visual - Sports developmental testing scale, Amsterdam, neuropsychological, Memory Checklist for children, and the children's behavior questionnaire development of the MCC visual - motor integration, attention, motor MCCC1 coordination, as well as ability to execute, memory, and behavior to be checked.The results showed that 16% of patients reduced the cooperation time or completed the follow-up examination (n = 113), resulting in only 569 patients received follow-up check. Randomized after a median follow-up period (interquartile range [IQR]) of 3.9 (3.8-4.1) years, the researchers observed, the ICU group TGC did not affect the total IQ score (median [IQR], 88.0 [74.0-100.0] vs UC group 88.5 [74.3-99.0]; P = .73), did not increase the incidence of adverse outcomes (death or severe disability exclude neurocognitive examination: 19% [68/349] vs UC group 18% [63/351]; risks advantage after correction than 0.93; 95% CI, 0.60-1.46; P = .72). The researchers found that other intelligence score, as the move to integrate developmental score, memory score no difference between the groups. Tight glycemic control can improve motor coordination (from 9% [95% CI, 0% -18%] increased to 20% [95% CI, 5% -35%], all P ≤ .03) and cognitive flexibility (19% [95% CI, 5% -33%], P = .02). The researchers observed, TGC cause short and mild hypoglycemia and neurocognitive outcome independent of the deterioration.The researchers conclude, TGC treatment of ICU children's intellectual outcome did not deteriorate in the follow-up, compared with conventional treatment (UC) children.

Creative Biomart

HIV infection may be the main incentive for anal cancer

Fri, 23 Nov 2012 03:52:16 PDT

One study showed that, since the 1980s, with the HIV epidemic, the American male anal MARK2 cancer incidence significantly increase. However, the authors found that women with a high incidence of anal cancer in men, and their female incidence rate in the same period also increased, but HIV infection is not the reason.Meredith Shiels (National Cancer Institute, National Cancer Institute, Rockville, Rockville, Maryland, Maryland), and his colleagues used the HIV / AIDS Cancer Research HIV / AIDS Cancer Match (HACM) data collected from 1980 to 2005 , which contains the MARS data of the 17 HIV / AIDS Registry. During this period, there are 20,533 cases of anal cancer, of which 1665 (8.1%) cases occurred in patients with HIV infection.In the period from 1980 to 1984 and from 2001 to 2005, the incidence rate of anal cancer 0.44% up to 0.93%, while the proportion of the 100,000 male patients with anal MASTL cancer in HIV infected rose from 1.1% to 28.4%. Overall, 83.5% of HIV-infected patients with anal cancer gay.

The female anal cancer incidence is also elevated. The authors estimate that from 1980 to 1984 and from 2001 to 2005, the incidence of anal cancer from 0.68/100, 000 people rose to 1.29/100, 000 HIV-positive female patients with anal cancer ratio increased from 0% to 1.2%. Shiels and her companions anal MATK cancer in patients with HIV infection have a very large impact on the incidence of male patients, but had no effect on the rising incidence of anal cancer in women HIV-related diseases.Patients with anal cancer is relatively rare, but it is a common cancer HIV infection. The authors call this contact may spread in anal sex process and human papillomavirus (HPV) infection. HIV-related immune suppression may also weaken the body of the HPV immune response, to let HIV infection more likely to develop anal MAZ cancer.The researchers believe that their findings will potentially affect public health strategies such as the HPV vaccine. Effective measures to prevent HIV infection male anal cancer incidence significantly from the population level to reduce the incidence of anal cancer. "

Creative Biomart

Carbon ion radiotherapy limbs local primary sarcoma safe and effective

Wed, 21 Nov 2012 15:47:49 PDT

The purpose of this study is to determine the PIKFYVE carbon ion radiotherapy (CIRT) limbs local primary sarcoma treatment effect, the study was a prospective study. Shinji Sugahara, Radiother Oncol 10 online journals.In the period from April 2000 to May 2010, a total of 17 (12 men and 5 women) partial limb sarcoma patients receiving treatment CIRT. The age range of the subjects was 14 years old to 87 years old, and the median age was 53 years. Nine patients with initial onset, eight patients with PINK1 diseases husband recurrence. 8 of the 17 patients refused amputation, the remaining nine patients refused surgical resection. Four patients with tumors in the upper extremity, 13 patients with tumors in the lower extremities. Three patients with histological diagnosis of osteosarcoma, lymphosarcoma two patients, two patients with synovial sarcoma, 2 patients with rhabdomyosarcoma, two patients with PIR pleomorphic sarcoma the six patients promiscuous lesions. A limb acceptable CIRT dose of 52.8 GYE, 3 patients received a dose of 64 GYE, 13 patients received a dose of 70.4 GYE these therapeutic dose 16 in 4 weeks. The researchers conducted a review of treatment records and analysis of patient response to radiotherapy, local PITX1 tumor control and survival.

The follow-up time limits for the 11 months to 97 months, with a median follow-up time was 37 months. Radiotherapy response rate was 65%. 5-year local control rate was 76 percent. The 5-year overall survival rate was 56%. 17 patients, 10 did not appear to disease progression. Four patients with PKNOX1 local recurrence, one of whom once again to accept the CIRT treatment rescued, and the other three people died of systemic disease. To the long-term adverse reactions observed in the 6 patients. A three patients with femoral fractures, and 27 months after treatment in CIRT underwent surgery fixed. In the study, was not observed in the other three or more serious adverse reactions.The study concluded that, refused to accept the surgical treatment of patients with primary extremity sarcoma, CIRT is an effective and safe treatment modality.

Creative Biomart

Lurbinectedin can be an effective treatment of platinum resistant / refractory ovarian cancer

Tue, 20 Nov 2012 23:23:50 PDT

Lubrinectedin DNA double helix structure of the minor groove combination, PIBF1 tumor cells during mitosis distortion and ultimately apoptosis, and it could reduce cell proliferation. It has been a variety of tumors in vivo, especially in situ primary graft tumor cells showed activity.Findings for ovarian cancer cell lines (including platinum-resistant cancer cells), prompting researchers to explore further on the efficacy of the 22 advanced platinum-resistant or refractory ovarian cancer, mainly observed tumor response rate.2012 European Society for Medical Oncology Congress Vienna, published a clinical effect Lurbinectedin advanced platinum-resistant or refractory ovarian PIGO cancer. Trial, patients previously had undergone chemotherapy less than three major organ function and performance status ECOG score between 0-2. 15 (68%) bit experienced first chemotherapy patients and 7 (32%) experienced two serious illness chemotherapy patients involved in the study. Six pairs last platinum-containing chemotherapy (platinum resistant) patients with no response, and 16 patients with PIH1D1 platinum-resistant patients, which is thought to disable platinum-based chemotherapy interval is less than 6 months.Patients between the ages of 35-77 years old, with an average age of 59 years old. In these 22 patients, six eased condition (2 According to Rustin standard, four cases according to RECIST criteria), the overall response rate was 27%, one patient had a complete remission of Radiology. 6 patients (27%) in the initial assessment of PIK3C2B progress, overall disease control rate was 73%.In order to confirm the results of the first phase of the research, a phase II clinical trial was conducted in April 2012, an increase of 60 the random use lubrinectedin or Billiton parked irinotecan therapy patients. Preliminary toxicity data, despite appropriate preventive measures, or bone marrow suppression, nausea / vomiting, which fatigue is the most common drug-related toxicity. The pharmacogenomics analysis is used to identify potential biomarker compounds.

The comprehensive on, lurbinectedin activity in PIK3R4 platinum resistant / refractory ovarian cancer patients, compared treatment with topotecan ongoing evaluation. Dr. Cristiana Sessa plan the next step is to study its effect with platinum-containing chemotherapy combination therapy, and to further study its efficacy in ovarian cancer and pancreatic cancer. Additional data before it is needed, especially to compare with trabectedin (with or without cisplatin) treatment of ovarian xenograft tumor effect, confirm the results of pre-clinical studies tolerated epithelial ovarian cancer, evaluation and trabectedin drug distinction on behalf of the dynamics.

Creative Biomart

50% increase in HIV-positive hospitalized patients with myocardial infarction mortality

Thu, 15 Nov 2012 06:54:37 PDT

On Antimicrobial Agents and Chemotherapy interdisciplinary annual meeting of a secondary analysis of the National Inpatient Sample database, the risk of PHF1 death of HIV-positive patients with acute myocardial infarction (MI) in hospitalized patients is 53% higher than the negative. HIV-positive and-negative patients with nosocomial acute MI mortality were 4.3% and 2.4%, a significant difference.In this study, California, the Riverside County Department of Public Health, Dr. Daniel Pearce and his colleagues analyzed the nation from 1997 to 2006, all non-federal, short-term, comprehensive and the adult specialty hospitals treated about 1.5 million cases (nearly 20% of the sub-layer samples) acute MI adult patients hospitalized for more than one day.After adjustment for PHF21A age, race, sex, comorbidities, and type of insurance (socio-economic status indicators) effects found 5984 cases of HIV-positive patients with MI risk of death (HR) was 53% higher than the HIV-negative patients.

Compared with HIV-negative patients, HIV-positive patients was significantly younger (mean 64 years vs. 54 years), a higher proportion of PHF5A males (65% vs. 72%), and participate in the health insurance higher proportion (62% vs 25 %).Comorbidity burden of HIV-positive patients than HIV-negative patients, two groups of PHOX2A average Charlson comorbidity index score of 1.14 and 0.94, respectively. HIV-positive patients, the incidence of significant complications including kidney disease (13% vs. 5%), mild liver disease (8% vs. 1%) and heart failure (26% vs 20%) higher than that of HIV-negative patients. The proportion of HIV-positive patients with hypertension, diabetes and the most common cardiac arrhythmia metabolic risk factors lower than the HIV-negative patients. The proportion of PI15 substance abuse in HIV-positive patients than in HIV-negative patients.Pearce Dr speculated that the higher mortality rate of HIV-positive patients may be related to pathological effects on cardiovascular function and HIV viremia.

Creative Biomart

Exome sequencing is an effective diagnostic strategies for patients with severe mental retardation

Wed, 14 Nov 2012 17:44:19 PDT

Mental retardation with a wide range of PGM2 clinical and genetic heterogeneity, and thus the main cause of the disease is not yet clear. Netherlands Institute of Human Genome Veltman Dr. depth study found that the new mutation is an important cause of mental retardation; exome sequencing is found that these mutations are effective diagnostic strategies. Paper published in the online edition of the International magazine, NEJM, 2012 October 1, 2009 on.The researchers assessed the mentally retarded patients side by PGM3 side in addition to the known pathogenic factors. IQ lower than 50 patients, and the IQ normal parents included in the 100 cases, and more than 21,000 of the coding region of the gene sequencing. The researchers use data analysis procedures Novo Mutations in autosomal recessive mutation, X-sex-linked mutations were identified and classified. In addition, the researchers also used high-throughput confirmed 765 cases of PGRMC2 mentally retarded patients (diagnosed) alternative gene rearrangement. Mutation assessment completed by molecular geneticists and clinicians in the test is done on the basis of the patients' informed consent.

The results showed that 53 subjects in 100 cases, the researchers identified 79 new hair mutation. 10 Novo Mutations and three X-linked (maternal inheritance) mutation, 13 patients in the PHB trial found that previously reported may affect the function of the mental retardation gene mutation. Found in 22 patients after the election potentially pathogenic Novo Mutations in the gene pool. Population of patients diagnosed with similar phenotype, researchers from the candidate gene library identified three previously undiscovered new mutation, which confirmed that the mutations of PHC1 these genes may be the cause of mental retardation. Found no pathogenic autosomal recessive mutation in the observed population. Such trials in total diagnosis income was 16%, most of which involve the new mutation.Thus, we can conclude that the new mutation is an important cause of mental retardation; exome sequencing is found effective diagnostic strategy for these mutations.

Article resource: creative biomart

Localized Ewing's sarcoma in patients with intensive chemotherapy, the prognosis is good

Tue, 13 Nov 2012 23:23:23 PDT

The conventional methods of treatment of localized Ewing's sarcoma of North America, - multi - cyclophosphamide, doxorubicin, and ifosfamide, vincristine - etoposide alternating chemotherapy, as well as treatment by PEX6 surgery and / or radiotherapy to the primary tumor. Published in the Journal of Clinical Oncology Journal, October 22, 2012 "(Journal of Clinical Oncology), a study of the University of Pennsylvania, Children's Hospital of Philadelphia Richard B. Womer et al. The researchers through compression treatment interval conduct intensive chemotherapy, to test whether the method can improve the prognosis of PGA3 patients.The study was a prospective, randomized controlled trials, patients younger than 50 years old to participate in trials, patients with Ewing's sarcoma are newly diagnosed local film. Patients were assigned to receive conventional treatment and intensive treatment for 21 days and 14 days, respectively, two sets of PGA5 chemotherapy cycles, patients addicted absolute neutrophil count requirements greater than 750 × 106 / L, platelet count greater than 75 x 109 / L. The patients received 14 cycles of vincristine (2 mg/m2), doxorubicin (75 mg/m2), cyclophosphamide (1.2 g/m2) and ifosfamide (9 g/m2), etoposide glycosides (500 mg/m2) alternating treatment, treatment during the week with filgrastim (5 mg / kg per day; maximum dose of 300 mg) for PGAP1 treatment. After 13 weeks (conventional treatment group after four cycles, six cycles of intensive therapy group) the primary tumor treatment (surgery, radiation therapy, or a combination of both). The primary endpoint of the study and event-free survival rate (EFS). (The study in ClinicalTrials.gov ID NCT00006734).

The study recruited a total of 587 patients, of which 568 cases eligible patients, these patients were randomly assigned 284 patients per treatment group. Cycle of treatment cycle of the PGM1 conventional treatment group median interval of 21 days (average 22.45 days); strengthen the treatment group median interval of 15 days (an average of 17.29 days). The study found that the conventional treatment group median EFS was 65% in five years, and strengthen the treatment group was 73% (P = .048). Toxicity similar between the two treatment methods.The researchers believe that the biweekly chemotherapy treatment toxicity does not increase at the same time, the efficacy of the treatment of localized Ewing's sarcoma is superior to chemotherapy once every three weeks.

Article resource: creative biomart

Carbon ion radiotherapy is safe and effective on the limbs local primary sarcoma

Mon, 12 Nov 2012 18:03:18 PDT

The purpose of this study is to determine the PELP1 carbon ion radiotherapy (CIRT) limbs local primary sarcoma treatment effect, the study was a prospective study. Shinji Sugahara, Radiother Oncol 10 online journals.In the period from April 2000 to May 2010, a total of 17 (12 men and 5 women) partial limb sarcoma patients receiving treatment CIRT. The age range of the subjects was 14 years old to 87 years old, and the median age was 53 years. Nine patients with PEPD initial onset, eight patients with diseases husband recurrence. 8 of the 17 patients refused amputation, the remaining nine patients refused surgical resection. Four patients with tumors in the upper extremity, 13 patients with tumors in the lower extremities. Three patients with histological diagnosis of osteosarcoma, lymphosarcoma two patients, two patients with synovial sarcoma, 2 patients with PER2 rhabdomyosarcoma, two patients with pleomorphic sarcoma the six patients promiscuous lesions. A limb acceptable CIRT dose of 52.8 GYE, 3 patients received a dose of 64 GYE, 13 patients received a dose of 70.4 GYE these therapeutic dose 16 in 4 weeks. The researchers conducted a review of treatment records and analysis of patient response to radiotherapy, local PET112 tumor control and survival.

The follow-up time limits for the 11 months to 97 months, with a median follow-up time was 37 months. Radiotherapy response rate was 65%. 5-year local control rate of 76%. The 5-year overall survival rate was 56%. 17 patients, 10 did not appear to disease progression. Four patients with local recurrence, one of whom once again to accept the CIRT treatment rescued, and the other three people died of PEX10 systemic disease. To the long-term adverse reactions observed in the 6 patients. A three patients with femoral fractures, and 27 months after treatment in CIRT underwent surgery fixed. In the study, was not observed in the other three or more serious adverse reactions.The study concluded that, refused to accept the surgical treatment of patients with primary extremity sarcoma, CIRT is an effective and safe treatment modality.

Article resource: creative biomart

Whole-genome sequencing found that the sensitivity of the genetic basis of everolimus

Sun, 11 Nov 2012 21:43:27 PDT

New treatment of the lack of drug development may be to slow partly responsible for PCDHGC3 bladder cancer mortality declined. In addition, the disease is highest recurrence rate, the majority of patients with bladder cancer (about 50% to 70%) in all cancer have disease progression or relapse experience.David Solit, Gopa lyer and collaborators to assess mTOR inhibitor everolimus as with PCGF2 drugs, for the treatment of progressive, metastatic bladder cancer, the role of this Phase II clinical trial results occurs interest. In the test, a patient one year after the start of treatment, drug treatment complete response. They hypothesized that the PCK1 tumor of the patient specific genetic defects lead to its high response to treatment.In order to verify this hypothesis, the researchers used whole-genome sequencing of the patient's tumor tissue and peripheral blood DNA sequencing. They were detected to 17,136 somatic mutations, in which they found in the TSC1 (tuberous sclerosis complex 1) two base pair deletion in the PCSK6 gene, the gene has been found to occur in the bladder cancer in previous studies mutation, deletion mutation in the gene are also believed to cause the activation of the mTOR pathway. TSC1 gene suppression of bladder PCTP cancer cell lines, led to the increased sensitivity of mTOR inhibitors.

The researchers have tried for more analysis by everolimus treatment in patients with tumors in the two clinical trials with. The targeted sequencing shows, in the analysis of 109 tumors, 8% TSC1 mutations and TSC1 mutations there is a correlation between the everolimus sensitivity. There are four pairs of Everolimus low therapeutic response in patients TSCI mutations occurred in 9 tumors progress of patients, 8 patients TSC1 to wild-type. TSC1 mutations in the recurrence time there is a significant delay (4.1 months vs 1.8 months).
The findings of the study published in Science magazine. The results underscore the importance of the identification of the molecular characteristics of the tumor, and that whole genome sequencing for the applicability of identification has not been previously probe cleared the drug sensitivity biomarkers in clinical institutions, these markers may help identify those who are more likely to target anticancer drug response patients.

Article resource: creative biomart

Long-term prognosis of left ventricular electrode position and left ventricular pacing QRS morphology affect CRT

Thu, 08 Nov 2012 17:48:41 PDT

For certain patients with heart failure, PCDHB3 cardiac resynchronization therapy (cardiac resynchronization therapy, CRT) can significantly improve symptoms and improve survival. Different patients, however, different for the CRT reactive variety of reasons affecting CRT effect wherein surgery-related features, such as the location of the left PCDHGA1 ventricular electrode, the electrode positions of the right ventricle, the left ventricular pacing of QRS wave morphology may affect the long-term prognosis of the CRT , but there is still a lack of research.Accordingly, Jastrzebski M, etc. was a single-center retrospective study, the study was designed to explore the CRT preoperative characteristics, the CRT procedure-related characteristics of the PCDHGA2 long-term prognosis, the CRT procedure-related features include: left ventricular electrode position, the left ventricle from the stroke QRS complex morphology, the distance between the right ventricular electrode position and left and right ventricular electrode.

Long-term prognosis of left PCDHGA5 ventricular electrode position and left ventricular pacing QRS morphology affect CRT
Study selected the 6 years, 362 cases of CRT patients, all patients were recorded CRT preoperative electrocardiogram, ECG left ventricular pacing alone and biventricular pacing ECG; through simple left PCDHGA8 ventricle pacing the ECG may determine left ventricular pacing site when V1 All patients the V2 lead QRS wave are positive, suggesting that pacing site after sidewall non-apical, V1 or V2 QRS wave is negative, suggesting that apical pacing sites in the left ventricular anterior; X-ray images to determine the position of the left ventricular electrode and the right ventricular electrode; using the Kaplan-Meier method assessed using univariate and multivariate Cox proportional hazards models to assess all-cause mortality / rehospitalization rate and cardiovascular mortality / rehospitalization rate related images factors.The research results are as follows: average follow-up time of 27.4 ± 16.9 months, including 79 deaths, 62 cases of cardiovascular death, the 99 unplanned readmission, 1-year and 2-year all-cause mortality was 8.2% and 18.0% . Left ventricular pacing ECG morphology and left ventricular electrode position predictor of death and sicker patients, the the univariate model prompted, the apical pacing shape of the left ventricular anterior cardiovascular death hazard ratio of 1.8, the risk of a multivariate model ratio was 1.7. Univariate models suggest that the left ventricular electrode located in the interval the Ministry and the apex of cardiovascular death hazard ratio of 2.1, a multivariate model, the hazard ratio 1.9.The following conclusions can be drawn from the study: left ventricular anterior apical pacing QRS complex morphology and left ventricular electrode located in the interval of the Ministry and the apical CRT impact of CRT can be long-term prognosis, to prevent this from happening in the CRT surgery .

Article resource: creative biomart

Bilateral Cardiac Sympathetic Denervation Surgery to Refractory Ventricular Tachycardia

Fri, 05 Oct 2012 00:32:06 PDT

The sympathetic nervous system plays an important role in ventricular TIMP2 heart merits and demerits speed. Left ventricular sympathetic denervation surgery (LCSD) can reduce the incidence of ventricular tachycardia and sudden cardiac death caused due to severe ventricular tachycardia. But when the LCSD on the suppress ventricular tachycardia invalid, then attach the line right heart to sympathetic surgery may be an optional program. Bilateral cardiac sympathetic denervation surgery (BCSD) to treat ventricular tachycardia in the safety and feasibility of the body's unclear.The researchers designed a TIMP3 clinical study to clear bilateral cardiac sympathetic denervation surgery on sustained ventricular tachycardia emergency control role. Patient data, including a review of 6 patients with bilateral cardiac sympathetic denervation surgery who has line left heart to the sympathetic surgery LCSD failure before right heart sympathetic denervation surgery RCSD patients showed an electrical storm attack, including continuing ventricular tachycardia or recurrent TIPARP ventricular fibrillation. 5 males, females, average age 60.1 years, mean left ventricular ejection fraction was 25.8%.6 patients, 5 called monomorphic ventricular tachycardia, four of whom had undergone endocardial chamber speed ablation surgery, 2 had line epicardial ventricular tachycardia ablation surgery, postoperative closely monitored to correct all reversible factors VT persists. All patients received a maximum tolerated dose of beta blockers governance (50% for metoprolol, 50% for carvedilol) and Cordarone therapy. Half of the patients using lidocaine and / or mexiletine. Other antiarrhythmic TJP1 drugs either contraindications or the patient's ventricular tachycardia invalid. Polymorphic ventricular tachycardia in patients 5 list, the researchers of the three patients with radiofrequency ablation, including a line endocardial and epicardial radiofrequency ablation. Another three patients radiofrequency ablation. Are all monomorphic ventricular tachycardia in patients undergoing general BCSD received radiofrequency ablation (average number of treatments was 2.2 ± 0.5 times / person). All patients were all not line treatment of TLK2 heart transplantation.In the case of all of the above treatment regimens were failed, the researchers consider patients underwent bilateral cardiac sympathetic denervation surgery sympathetic denervation (LCSD underwent right heart surgery). BCSD, 66.7% of patients, 16.7% of patients with a partial response, 16.7% of patients with completely invalid. ICD discharge or overdrive pacing completely disappeared in 3 patients, 1 patients reduced by half. Other patients from 11 defibrillator reduced to forbidding electric shock. Only one patient BCSD no response. All five patients in the BCSD after room speed reduction occurs smoothly discharged. One patient in the family asked to give up treatment. Two patients died after discharge, but it has nothing to do with the arrhythmia. No. 1 patient because of persistent heart failure deterioration, choose to accept hospice treatment. No. 6, died at home, the specific cause is unknown, ICD unrecorded died ventricular tachycardia or atrial tachycardia.Bilateral sympathetic denervation surgery, found no significant ECG physiological aspects of change, also found no persistent adrenal insufficiency performance. Two patients with surgery-related complications (increased postoperative heart failure and thoracoscopic surgery unilateral lung ventilation low tolerance).As far as we know, this is known up to the number of cases of bilateral cardiac sympathetic denervation surgery. The sample size is small, the general applicability is not high. Due to the lack of randomized and retrospective studies bias, inevitably some of the decision-making aspects of the research structure.The BCSD mechanism may include blocking the stellate ganglion remodeling, reducing myocardial cells or drug-induced arrhythmias stellate ganglion nerve signaling. A variety of evidence suggests that ventricular the BCSD surgery with antiarrhythmic effect.Animal experiments comparing the left ventricle, right ventricle and bilateral sympathetic denervation surgery showed bilateral sympathetic denervation surgery arrhythmia effect. Research on spinal cord stimulation and thoracic epidural anesthesia, according to reduce the heart's cardiac sympathetic tone overall, it was a strong cardioprotective effect.Ventricular tachycardia and ventricular fibrillation after heart transplantation sudden cardiac death in patients with relatively rare compared with the cardiac arrest pulse disappears, heart transplantation patients, sympathetic amputation.Our study suggests that other treatment options ineffective in patients with sustained ventricular tachycardia, BCSD may be intentional. Surgery is not in as serious complications, the prognosis is good. BCSD's role in the treatment of human cardiac arrhythmias, and also the need for further research. origin :creativebiobart Visit http://www.creativebiomart.net for details.

great tool to find conference and courses

Sat, 28 Apr 2012 02:36:59 PDT

Hey guys

Some people working at the NKI (Netherlands Cancer Institute) have setup a
search engine for scientific meetings. check the description and the website
as well, if interested...
This website, called biomeeter (www.biomeeter.com) is really well done as it
gives a nice overview of the upcoming meetings organized, and the search can
be done by field or keyword, or even by location (as it's always possible to
combine business with pleasure ;-)).
Another great characteristic of Biomeeter is that you can add yourself
meetings to the website and share the info. And last but not least: you can
get informed with an email alert about upcoming meetings in your field.
So, check it out and if you like it, spread the word in your lab and
institute!

University of Iowa, NYU biologists describe key mechanism in early embryo development

Thu, 20 Oct 2011 19:00:09 PDT

New York University and University of Iowa biologists have identified a key mechanism controlling early embryonic development that is critical in determining how structures such as appendages—arms and legs in humans—grow in the right place and at the right time. In a paper published in the journal PLoS Genetics, John Manak, an assistant professor of biology in the UI College of Liberal Arts and Sciences, and Chris Rushlow, a professor in NYU's Department of Biology, write that much research has focused on the spatial regulatory networks that control early developmental processes. However, they note, less attention has been paid to how such networks can be precisely coordinated over time. Rushlow and Manak find that a protein called Zelda is responsible for turning on groups of genes essential to development in an exquisitely coordinated fashion. "Zelda does more than initiate gene networks—it orchestrates their activities so that the embryo undergoes developmental processes in a robust manner at the proper time and in the correct order," says Rushlow, part of NYU's Center for Developmental Genetics. "Our results demonstrate the significance of a timing mechanism in coordinating regulatory gene networks during early development, and bring a new perspective to classical concepts of how spatial regulation can be achieved," says Manak, who is also assistant professor of pediatrics in the Roy J. and Lucille A. Carver College of Medicine and researcher in the UI Roy J. Carver Center for Genomics. The researchers note that their findings break new ground. "We discovered a key transcriptional regulator, Zelda, which is the long-sought-after factor that activates the early zygotic genome," says Rushlow. "Initially, the embryo relies on maternally deposited gene products to begin developing, and the transition to dependence on its own zygotic genome is called the maternal-to-zygotic transition," she adds. "Two hallmark events that occur during this transition are zygotic gene transcription and maternal RNA degradation, and interestingly, Zelda appears to be involved in both processes." The research showed that when Zelda was absent, activation of genes was delayed, thus interfering with the proper order of gene interactions and ultimately disrupting gene expression patterns, the researchers noted, adding that the consequence to the embryo of altered expression patterns is a drastic change in the body plan such that many tissues and organs are not formed properly, if at all. The researchers used Drosophila, or fruit flies, to investigate these regulatory networks. The fruit fly has the advantage of being a tractable genetic model system with a rapid developmental time, and many of the genetic processes identified in flies are conserved in humans. Additionally, pioneering fly research has led to many of the key discoveries of the molecular mechanisms underlying developmental processes in complex animals. The study brought together Rushlow, who discovered Zelda and is an expert in genetic regulatory networks in development, and Manak, a genomics expert whose laboratory focuses on how a genome is constructed and coordinately functions. "I had always wanted to work with Chris, and this was a wonderful opportunity for us to combine our complementary areas of expertise in a truly synergistic fashion," says Manak. "Our collaboration is a marvelous example of how a problem can be viewed from two different perspectives, a systems view of early gene networks and an individualistic view of single genes and single embryos, and result in novel and significant discoveries," says Rushlow.

New 'bouncer' molecule halts rheumatoid arthritis

Wed, 07 Sep 2011 17:14:25 PDT

Researchers at Northwestern University Feinberg School of Medicine have discovered why the immune cells of people with rheumatoid arthritis become hyperactive and attack the joints and bones. The immune cells have lost their bouncer, the burly protein that keeps them in line the same way a bouncer in a nightclub controls rowdy patrons. The Feinberg School team has identified this bouncer, a protein called P21, which prevents immune cells from launching into their destructive rampage through the cartilage and bone. When the scientists developed and injected an imitation of the protein into an animal model of rheumatoid arthritis, the disease process was halted. "The bouncer molecule stopped the immune cells from going crazy," said lead author Harris Perlman, associate professor of rheumatology at Northwestern's Feinberg School. "Imagine destructive customers in a bar, and the bouncer says, 'You are going to behave!' That's P21. This discovery opens up a new avenue for future therapies, which are greatly needed for rheumatoid arthritis." Previous research by the Feinberg team showed people with rheumatoid arthritis were low in P21, but the protein's role was unknown. The new study, which will be published in the journal Arthritis & Rheumatism, reveals the protein's vital role in keeping the immune cells in check. Currently, there is no effective, nontoxic way to stop the hyperactive immune cells, Perlman said. To develop the new approach, Perlman and his team tested five different parts, called peptides, of P21. He slipped each peptide into a "ghostlike" molecule that he injected into mice with a rheumatoid arthritis-like disease. The molecule secretly infiltrated the immune cells. After the seven-day trial, one of the tested peptides had calmed the overactive immune cells without toxic effects. Next, Perlman plans a 30-day study with the same peptide to monitor efficacy and toxicity over a longer period of time. Existing treatments for rheumatoid arthritis include low-level chemotherapy and steroids. These are not always effective, however, and they are frequently accompanied by side effects. A newer class of therapy, which is sometimes used in combination with chemotherapy and steroids, is biologic response modifiers. These are antibodies or other proteins that reduce the inflammation produced by the hyperactive immune cells. These biologics don't work for everyone, though, and can be associated with side effects including the risk of infection.

Researchers publish study on neuronal RNA targeting

Wed, 07 Sep 2011 17:12:00 PDT

SUNY Downstate scientist Ilham Muslimov, MD, PhD, along with senior author Henri Tiedge, PhD, professor of physiology and pharmacology and of neurology, published a study suggesting that cellular dysregulation associated with certain neurodegenerative disorders may result from molecular competition in neuronal RNA transport pathways. The paper appeared in the Journal of Cell Biology, titled, "Spatial Code Recognition in Neuronal RNA Targeting: Role of RNA-hnRNP A2 Interactions." The article was highlighted in an accompanying editorial, "RNA Targeting Gets Competitive." Dr. Tiedge notes, "In contrast to DNA, in which information coding is one-dimensional (i.e. linear), RNA can encode information in three-dimensional architectural motifs. Dr. Muslimov has now identified RNA motifs that act as spatial codes in nerve cells, directing RNA to dendrites and synapses." A synapse is a junction that allows a neuron (nerve cell) to pass an electrical or chemical signal to another cell, and dendrites are the branched processes of neurons that act to conduct electrochemical stimulation to the neuronal cell body. He adds, "Just like number 7 on a New York subway train is a code for the destination 'Times Square,' Dr. Muslimov's RNA motifs are codes for the dendrite and synapse destinations. They make sure RNAs are delivered to cellular sites where they are supposed to operate." "Sometimes, an RNA may express an inappropriately high number of targeting motifs, with the result that the resources of the transport system become overwhelmed. It is as if too many passengers are trying to enter trains at the same time, exceeding system capacity. We have congestion, and transport is disrupted." Dr. Tiedge explains that Dr. Muslimov's work indicates that in nerve cells, excessive competition for common transport resources may result in compromised dendritic delivery of RNA. "In the example Dr. Muslimov studied, the culprit is an RNA that contains the genetic information for the fragile X mental retardation protein. Once the number of motifs structures in this RNA exceeds a threshold (usually around 55), the RNA becomes excessively competitive and begins to commandeer, at the expense of other RNAs, common resources of the cellular transport system." "Dr. Muslimov's data raise the possibility that the resulting neurodegenerative disease, the fragile X-associated tremor/ataxia syndrome, is precipitated by a neuronal transport problem," Dr. Tiedge concludes.

Researchers explain how railways within cells are built in order to transport essential cargos

Fri, 02 Sep 2011 18:45:31 PDT

Every cell in the human body contains a complex system to transport essential cargoes such as proteins and membrane vesicles, from point A to point B. These tiny molecular motor proteins move at blistering speeds on miniature railways carrying components of the cell to their proper destinations. But just how cells construct these transport railways to fit precisely inside of confined spaces of the individual cells has been a complex question, as it is critical that these railways do not grow too long or come up too short, as that would cause a misdirection of the proteins being transported. Bruce Goode, professor of biology, working in collaboration with the labs of Laurent Blanchoin (Grenoble, France) and Roland Wedlich-Soldner (Munich, Germany), have come one step closer to understanding the elusive mechanics of this process. In a recent paper published in Developmental Cell, a team led by Goode's Ph.D. student Melissa Chesarone-Cataldo shows that the length of the railways is controlled by one of its "passengers," which pauses during the journey to communicate with the machinery that is building the railways. "The frequency of these chats between the passengers and builders may provide the feedback necessary to say a railway is long enough, and construction should now slow down," says Goode. Much like a real construction site, a system must be in place with roadways and transporters to move the building materials. In this case, cellular proteins called actin cables act as the roadways, and the transporters are myosin molecules, nanoscale motor proteins that rapidly deliver critical cargoes to one end of a cell. Each cable is assembled from hundreds or thousands of copies of the actin, which is called a helical filament. Nine years ago, Goode and his colleagues discovered that a family of proteins called formins stimulate the rapid growth of actin filaments. Recently, the team began to question how a cell controls the power of formins, which tell them when to speed up, when to slow down, when to stop altogether. Enter Smy1, a myosin-passenger protein. Goode and his colleagues hypothesized that a passenger protein like Smy1 would provide the perfect mechanism for slowing down formins when roadways are longer and would be carrying more passengers. They tested their theory in yeast cells, where formins construct actin cables that transport building materials essential for cell growth and division. As Goode says, they struck gold. When they deleted the gene for Smy1, cables grew abnormally fast and hit the back of the cell, buckling and misdirecting transport. When they purified Smy1 and placed it in a test tube with formins they discovered that Smy1 slows down actin filament growth. To further explore, they tagged Smy1 in living cells and learned that Smy1 molecules are carried on cables by myosin to the formin, where they pause for 1-2 seconds to give formins the message to slow down. Goode says their working model illustrates that as a cable grows longer, it loads up more and more Smy1 molecules, which are transported on the cable to send a message to the formin to slow down. "This prevents overgrowth of longer cables that are nearing the back of the cell, but allows rapid growth of the shorter cables," says Goode. This paper will help scientists understand the general mechanisms that are used for directing cell shape and division. The next challenge says Goode, is "to find out whether related mechanisms are used to control formins in mammalian cells and understand the physiological consequences of disrupting those mechanisms."

Enzymes for cell wall synthesis conserved across species barriers

Thu, 14 Jul 2011 19:07:26 PDT

Cell walls are referred to as primary or secondary according to their materials and characteristics. While the cell is still growing it is only surrounded by the elastic and flexible primary cell wall. When the cell is fully grown, certain types of cells, for example the water transporting vessels, form a rigid secondary cell wall. The most important component of both cell wall types is cellulose........> Full story

Sniffing out calories: Hormone linked to nose's ability to locate food

Tue, 12 Apr 2011 20:11:09 PDT

The hormone ghrelin, known to promote hunger and fat storage, has been found to enhance exploratory "sniffing" in both animals and humans. The research, by University of Cincinnati (UC) scientists, suggests that ghrelin may be designed to boost detection of calories in our environment through smell and link those inputs with natural regulation of metabolism and body weight. Led by Jenny Tong, MD, and Matthias Tschöp, MD, both of UC's endocrinology, diabetes and metabolism division, the study appears in the April 13, 2011, issue of The Journal of Neuroscience, the official journal of the Society for Neuroscience. "Smell is an integral part of feeding and mammals frequently rely on smell to locate food and discriminate among food sources," says Tong. "Sniffing is the first stage of the smell process and can enhance odor detection and discrimination." The research team tested both rats and humans. Rats were given ghrelin and monitored for sniff frequency using a video-based behavior analysis system set to record the movement of the nose tip. The investigators also measured the ability of the rats to detect specific odors mixed in water. Human subjects were evaluated before and after ghrelin infusion using a sniff magnitude test (SMT) developed at the University of Cincinnati by co-investigator Robert Frank, PhD. Subjects were instructed to take a natural sniff of several odorants using the SMT canister and rate the smells in order of pleasantness. Software connected to the canister allowed researchers to measure sniff pressure to determine overall sniff magnitude. Data for both humans and rats show ghrelin enhanced odor detection and exploratory sniffing. "Other studies have shown that hunger can enhance odor detection and sniffing in animals," says Tschöp. "Since ghrelin is a hunger-inducing stomach hormone that is secreted when the stomach is empty, this hormone pathway may also be responsible for the hunger-induced enhancement of sniffing and odor detection." The scientists say this study could open up new avenues connecting metabolic control, chemo-sensation and behavioral neuroscience research. Future studies will explore the exact molecular pathways through which ghrelin affects sniff behavior.

Rethinking reprogramming: A new way to make stem cells

Fri, 08 Apr 2011 19:29:35 PDT

A paper published by Cell Press in the April 8th issue of the journal Cell Stem Cell reveals a new and more efficient method for reprogramming adult mouse and human cells into an embryonic stem cell-like state and could lead to better strategies for developing stem cells for therapeutic use. The ability to reprogram adult cells into cells that resemble embryonic stem cells has tremendous potential for both stem cell research and regenerative medicine. "Previous studies have demonstrated the usefulness of iPSCs not only in the study of basic stem biology, but also in the ability to generate patient-specific iPSC clones, which can then be further differentiated into the cell type of choice, such as blood, heart or liver cells," explains senior study author, Dr. Edward E. Morrisey, from the University of Pennsylvania. "However, at this point the low efficiency of iPSC reprogramming is a major impediment to adapting the process to large scale studies." Scientists already knew that microRNAs (miRNAs), small non-coding pieces of RNA that regulate gene expression, can enhance traditional cellular reprogramming methods. Dr. Morrisey and colleagues decided to look at whether miRNAs could directly reprogram mature mouse and human cells to a pluripotent stem cell state on their own, without adding any of the other reprogramming factors that are usually used to make iPSCs. Surprisingly, they found that a specific group of miRNAs can indeed reprogram mouse and human adult cells into an iPSC state by themselves, and can do so very rapidly and efficiently. The researchers went on to show that suppression of a chromatin remodeling enzyme called Hdac2 is a necessary part of this miRNA-mediated reprogramming process. The findings suggest that it may be possible to produce iPSCs without forcing the expression of multiple stem cell-associated transcription factors. "Taken together, our results show that miRNA and Hdac-mediated pathways can cooperate in a powerful way to reprogram somatic cells to pluripotency, without the need for pluripotent factors," concludes Dr Morrisey. "The current focus on developing miRNAs for therapeutic use could lead to a rapid miRNA/small molecule approach for iPSC reprogramming."

Chimp, bonobo study sheds light on the social brain

Tue, 05 Apr 2011 19:04:41 PDT

It’s been a puzzle why our two closest living primate relatives, chimpanzees and bonobos, have widely different social traits, despite belonging to the same genus. Now, a comparative analysis of their brains shows neuroanatomical differences that may be responsible for these behaviors, from the aggression more typical of chimpanzees to the social tolerance of bonobos. Read more

Mutant prions help cells foil harmful protein misfolding

Mon, 21 Mar 2011 03:18:09 PDT

Romping clumps of misfolded proteins are prime suspects in many neurological disorders including Alzheimer's, Parkinson's, and Creutzfeld-Jakob Disease. Those diseases are devastating and incurable, but a team of biologists at Brown University reports that cells can fix the problems themselves with only a little bit of help. The insight suggests that there are more opportunities to develop a therapy for protein misfolding than scientists had thought. "There are multiple steps that you could target," said Susanne DiSalvo, a Brown biology graduate student and lead author of a paper published in advance online March 20 in Nature Structural and Molecular Biology. In the study, the research team, led by Tricia Serio, associate professor of medical science, explains how two different beneficial mutant prions managed to foil the amplification of harmful clumps of misfolded proteins in yeast. Cells have an internal quality assurance system to break up and refold misfolded proteins, but that system can be overwhelmed by diseases. DiSalvo was the first to observe that the mutants act at distinct stages to tip the balance back in favor of the cells, allowing them to overcome the problem. Serio says the molecular mechanisms appear to explain how similar mutants solve protein misfolding in mammals, including people. The phenomenon had been poorly understood and has never been exploited to develop a successful therapy. Misfolding is a vulnerable process Until now most scientists guessed that the only way to stop the runaway misfolding was right at the beginning and assumed the mutants must be blocking that first step to keep the protein in a harmless form. DiSalvo's work instead suggests that there are many opportunities throughout the process where even a mild intervention could give cells what they need to gain the upper hand, Serio said. "That's one of the biggest outcomes of Susanne's work: that if you just even slightly interfere with this process, the cell can deal with it and get rid of it," Serio said. "The dogma in the field is that these conformations were so abnormal the cell couldn't resolve them. But what we've found is that this process of misfolding is so efficient the cells can't keep up with it. If you make it even just a little bit less efficient the cell can get rid of the pathological state." One mutant prion, Q24R, hinders the ability of misfolded proteins to aggregate into harmful clumps. It's like a dryer sheet that cuts down on static cling and makes it easier to fold laundry. Another helpful mutant prion known as G58D, assists the cell by speeding up its ability to unfold and refold misfolded proteins. That's more like a friend who helps untangle strings of holiday lights when they come out of storage. DiSalvo's experiments showed how the mutants and cells work together. Cells would only be cured when she both added a mutant and allowed the cells' own quality assurance system to work. Adding the mutant G58D, for example, could cure a cell of infection by the Sup35 prion, but if she perturbed the cell's quality assurance system then G58D would not work. The results show the importance of delving deeply into molecular networks, said Stefan Maas, who oversees Serio's and other cellular signaling grants at the National Institutes of Health. "These results are a great example of the power of system-level studies," Maas said. "By showing how two beneficial mutants cure the cell of prions, this study has revealed that small changes applied to distinct components of a molecular network can dramatically alter the outcome for the cell. These new insights may lead to new strategies for preventing or treating disorders that involve protein deposits." But those strategies may require turning proteins into pills. Serio noted that while beneficial mutant prions confer resistance to prion infection in nature, they haven't been successful in reversing an established infection because sustained delivery into the body is too challenging. However, a small molecule drug mimic, if developed, could target infected tissues more effectively over a longer period to slow or perhaps even reverse disease progression. In the paper the researchers conclude, "A system-based approach to prion intervention represents a potentially promising direction in which to explore future therapies."

Pig model of cystic fibrosis improves understanding of disease

Thu, 17 Mar 2011 03:15:28 PDT

It's been more than 20 years since scientists first discovered the gene that causes cystic fibrosis (CF), yet questions about how the mutated gene causes disease remain unanswered. Using a newly created pig model that genetically replicates the most common form of cystic fibrosis, University of Iowa researchers have now shown that the CF protein is "misprocessed" in the pigs and does not end up in the correct cellular location. This glitch leads to disease symptoms, including gastrointestinal abnormalities and lung disease in the pigs, which mimic CF in humans. The findings are published in the March 16 issue of the journal Science Translational Medicine. The findings match earlier laboratory experiments that suggested the gene mutation disrupts the process whereby the CF protein is folded into its correct shape and shipped to the membranes of cells that line the airways and other organs. When it is correctly located at the cell membrane, this protein -- called cystic fibrosis transmembrane conductance regulator (CFTR) -- forms a channel to allow chloride ions to move in and out of cells. This ion movement is a critical component of the system that maintains salt and water balance across cell membranes in the lung as well as other organs and supports normal membrane function including eradicating bacteria from cell surfaces. The new study shows that in pigs, the CFTR protein behaves the same way in a living animal as it does in experimental cell systems, suggesting that these experimental systems are useful for learning about the CFTR protein's properties. The cell systems and the new pig model may also be helpful in testing therapies designed to increase the amount of protein that gets to the cell membrane, or boost the activity of the protein that is located at the membrane. "Instead of just trying to treat the symptoms of CF, current research is moving toward therapies that target mutations in the CFTR gene," said David Stoltz, M.D., Ph.D., UI assistant professor of internal medicine and senior study author. "For example, there already are drugs known as "correctors" being tested. These drugs help CFTR move from inside the cell to its correct location on the cell surface. "The pig model could help us develop and test more corrector drugs, and it will also help us better understand why the protein is misprocessed in the first place," Stoltz added. "If we understand what is going wrong, we may be able to develop new therapies that can target the problem and allow more of the CFTR to make it to the cell surface, which may alleviate the disease symptoms." In 2008, the UI team and colleagues at University of Missouri created pigs that were missing the CFTR protein. These animals developed CF disease symptoms that closely mimicked the human disease. In the new pig model, the animals have two copies of the CFTR gene containing the most common CF-causing mutation, which is known as the delta F508 mutation. These pigs also develop CF symptoms similar to the human disease. In particular, the CF pigs are born with gastrointestinal disease and develop lung disease over time. By studying the protein in the pigs, the researchers were able to show that most of the CFTR protein is misprocessed and gets degraded, but a small amount of the protein does get to the cell membrane where it is able to form active chloride channels. However, the level of activity is only about 6 percent of the activity found in normal pigs with fully functional CFTR channels. The study shows that this small amount of CFTR activity is not sufficient to prevent CF disease in the pigs. CF is a recessive disease, meaning a person with one mutated copy and one good copy of the CFTR gene is a "carrier" but does not have CF. This suggests that 50 percent of normal CFTR activity is sufficient for health. The question has always been, 'Is there a minimal amount of active CFTR that would be enough to protect people from the disease symptoms?' "We know that people with 50 percent CFTR function have no disease, and now we know that 6 percent of full activity is not enough to prevent disease in the pigs," Stoltz said. "We still don't know how much CFTR is enough to prevent the disease, but this model animal could give us a way to investigate."

Understanding Immune Activation And Pathogenesis Of HIV Infection At Target Meeting

Thu, 03 Mar 2011 18:08:44 PDT

There are many stigmas and fears associated with AIDS and HIV prevailing in society in the current times. Several misconceptions have unnecessarily clouded people’s minds and have led to irrational thinking. Although the virus, as well as the syndrome, is quite serious and life-threatening, modern-day medicine has come a long way to neutralize some of these misconceptions. Understanding the disease, the disease causing viruses, and other details can make life easy and help eradicate myths about the disease. All this will be possible at the target meeting that aims at Understanding the Immune activation and pathogenesis of HIV infection scheduled to be held on March 12, 2011. Because this meeting will be held online, anyone interested in attending the meeting can join directly from their office, home, or anywhere that has an internet connection. Target Meeting is also calling for sponsors who would like to take initiative and support this great cause.

HIV (Human Immunodeficiency Virus), which is a member of the retrovirus family, causes AIDS (Acquired Immunodeficiency Syndrome.) The virus causes the immune system to fail, which further leads to life-threatening opportunistic infections. As a matter of fact, AIDS killed more than 25 million people between 1981 to 2006. Statistics also reveal that by 2009, more than 33.3 million people worldwide were infected with HIV. When you add these numbers together, you will find that HIV infects about 0.6% of the world's total population. According to the World Health Organization, HIV infection in humans is growing into a pandemic.

Based in Texas, the Target Meeting is a well-known online life science conference organizer. This online meeting aims at providing an innovative, informative, and interesting platform for HIV researchers and those suffering with HIV/AIDS so they get the maximum benefit without traveling a great distance to do so. It is an excellent opportunity to learn about the latest HIV progress and at the same time interact with top-level experts in a real time setting.

This online meeting is going to be a great platform for the HIV/AIDS community as you can communicate with leading researchers, scientists, and professors from all over the world. Some Keynote speakers include:

•Dr. Arup K. Chakraborty, Robert T. Haslam, Professor of Chemical Engineering, Chemistry, and Biological Engineering at MIT, USA.

•Dr. Suraiya Rasheed, Professor of Pathology, Director, Laboratory of Viral Oncology, University of Southern California, USA.

•Dr. Ruth M. Ruprecht, Professor, Dana-Farber Cancer Institute and Harvard Medical School, USA.

•Dr. Georges Herbein, Professor of Clinical Virology and Head of the Department of Clinical Virology at the University of Franche-Comté School of Medicine, France.

•Dr. Ivan Sadowski, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia, Canada.

•Dr. Yuntao Wu, Professor, Department of Molecular and Microbiology, George Mason University, USA and many other eminent personalities.

There is limited space left so if you want to be a part of target meeting, reserve your seat soon. There is no cost for attendees. Just visit targetmeeting.com and book your seat. After all, the best understanding of HIV/AIDS is by learning about this deadly virus, its effects, and how it gets transmitted. Please also come ahead for sponsoring this highly noble event. Your generous sponsorship would be highlighted in announcements to the community.

Contact:
Target Meeting
Address
Bellaire, Texas, 77401, USA
Email Address
Williams@targetmeeting.com

Enzyme cocktail could eliminate a step in biofuel process

Fri, 25 Feb 2011 03:30:49 PDT

Conversion of biomass to fuel requires several steps: chemical pretreatment to break up the biomass – often dilute (sulfuric) acid, detoxification to remove the toxic chemicals required in pretreatment, and microbial fermentation to convert the soluble sugars to fuels. Virginia Tech researchers have discovered an enzyme mixture that works in the presence of the toxic infused liquid biomass (hydrolysate), meaning that the detoxification step is unnecessary, reducing the cost of producing biofuels as well as increasing biofuel yields by avoiding the production of by-products and synthesis of cell mass. The research will be published in the Feb. 25 print issue of the journal Chemistry & Biology (www.cell.com/chemistry-biology). "Enzymes self-assemble a cell-free synthetic pathway; that is, we can put the desired biological reactions to work without the other complex interactions that take place within a cell," said Y.H. Percival Zhang, associate professor of biological systems engineering at Virginia Tech. "In microbial fermentations, glucose serves as both a growth substrate and a source of energy for generating a reduced power -- NADPH. In fact, only a small fraction of glucose is allocated to NADPH generation," he says. "The cell-free synthetic pathway process increases efficiency and reaction rate." "By using an enzyme cocktail consisting of 12 purified enzymes and coenzymes, this work has also demonstrated that the enzyme cocktail systems can work in the presence of microorganism-toxic compounds from dilute-acid pretreated biomass, suggesting that enzyme systems do not require high-purity substrates for biotransformation," said Zhang. "In other words, after pretreatment, we can do bioconversion directly, followed by chemical catalysis," he said. The article, "Biohydrogenation from Biomass Sugar Mediated by in vitro Synthetic Enzymatic Pathways," was written by Yiran Wang, research scientist in biological systems engineering at Virginia Tech; Weidong Huang, visiting scholar from the University of Science and Technology of China; Noppadon Sathitsuksanoh and Zhiguang Zhu; biological systems engineering Ph.D. students at Virginia Tech; and Zhang. A previously published article by Huang and Zhang compared the production of four biofuels – ethanol, butanol, fatty acide ethyl ester, and hydrogen, and report that hydrogen production through the synthetic pathway process is the most efficient for biofuels production. "Also, this analysis suggested that it was nearly economically impossible to produce advanced biofuels through aerobic fermentation as compared to anaerobic fermentations and enzyme cocktails," said Zhang.

Scripps Research study sheds light on RNA 'on/off switches'

Mon, 14 Feb 2011 03:20:51 PDT

Embargoed by the journal Nature Structural and Molecular Biology until February 13, 2011, 1 PM Eastern time – Scientists from The Scripps Research Institute have shed new light on a molecular switch that turns genes on or off in response to a cell's energy needs. The study—published February 13, 2011 in an Advance Online Publication of the journal Nature Structural and Molecular Biology—shows these recently discovered RNA "riboswitches" are capable of more complex functions than originally thought. In addition, because riboswitches so far have been found primarily in bacteria, the study may have implications for designing new antibiotics against harmful bacteria. "The study provides new insights into how a single RNA molecule can integrate both positive and negative signals from a cell," said senior author Martha Fedor, an associate professor and member of the Skaggs Institute for Chemical Biology at Scripps Research. "It extends the known capabilities of riboswitches." Riboswitches respond to the concentrations of molecules produced by a cell's metabolism—the process of creating or using energy—to regulate genes' activities. The new study shows that a particular riboswitch does not respond to just a single metabolite, as had been assumed, but rather to many such compounds. Switching Genes On and Off Each gene serves as a recipe for building a protein molecule. When a particular protein is needed by the cell, the corresponding gene, made of DNA, is turned "on," or transcribed into a messenger RNA, which then carries the "protein recipe" to the protein-making machinery of the cell. For many years scientists thought proteins, unlike DNA and RNA, were the only molecules in a cell capable of accomplishing sophisticated tasks, such as regulating the activities of genes or carrying out chemical reactions. But in the past couple of decades, researchers have discovered that certain types of RNA molecules are adept at performing feats worthy of their protein counterparts. Riboswitches are one such example. Discovered only about eight years ago, riboswitches are short stretches of RNA that reside within the messenger RNAs of proteins involved in a cell's metabolism. These riboswitches bind certain metabolites and, depending on how much binding occurs, the riboswitches turn the production of the corresponding proteins on or off. Until now, most researchers had assumed a single riboswitch was specific for a single metabolite. But the new study by Fedor's group shows a riboswitch can incorporate signals from many metabolites at once. A Self-Destructing Riboswitch Fedor's group was interested in studying the function of a type of riboswitch that binds to a metabolite called glucosamine-6-phosphate. This amino sugar, a building block for many glyosides and glycans, is required for the cell wall and other vital structures in bacterial cells. This particular riboswitch resides in the messenger RNA that carries instructions for the enzyme responsible for the production of glucosamine-6-phosphate, called GlmS. It was known that when glucosamine-6-phosphate is abundant in a cell, the riboswitch stops production of the GlmS enzyme by destroying itself and its messenger RNA. This self-destruction functions to shut off any more production of glucosamine-6-phosphate. On the other hand, when glucosamine-6-phosphate concentrations are low, the glmS riboswitch does not self-destruct, keeping the messenger RNA functioning. A Puzzling Observation Fedor and graduate student Peter Watson had designed an assay to measure the amounts of the glmS riboswitch in yeast cells as they added increasing concentrations of glucosamine. But the scientists stumbled on a puzzling finding. If they grew their yeast in energy-rich broth that contained glycerol, a 3-carbon energy source, the riboswitch behaved as they expected, shutting off the glmS messenger RNA in response to increasing glucosamine concentrations. However, if bacteria was grown in a broth containing glucose, a 6-carbon energy source, the riboswitch no longer self-destructed. "At first we thought something was wrong with our system," said Fedor. But Fedor and Watson solved the puzzle. They discovered this riboswitch can bind both glucosamine-6-phosphate and glucose-6-phosphate. Each compound, however, produces opposite results. Binding glucosamine-6-phosphate induces self-destruction of the riboswitch and turns the glmS gene off; binding glucose-6-phosphate prevents self-destruction and keeps the glmS gene turned on. "Scientists had long focused on the ability of riboswitches to recognize a single compound, but we have now found that riboswitches, or at least this one, can recognize multiple ones," said Watson. Integrating Signals "When glucose concentrations are high in a cell, it means that energy is abundant," explained Watson. "That is when cells would want to grow and divide and make more glucosamine-6-phosphate to build new cell walls. But when glucosamine-6-phosphate concentrations are high, then cells know to stop making more of this compound." The glmS riboswitch function thus depends upon a balance between these two—and possibly additional—competing signals. "This kind of complex signaling had long thought to be the domain of just proteins," said Fedor. "This is another example of a function thought to belong only to proteins that we now know that RNA can do." Fedor and Watson are now testing whether other types of riboswitches use this same mechanism. Unlike the glmS riboswitch, which self-destructs, most known riboswitches regulate the activities of their respective messenger RNAs by changing their three-dimensional structures in response to metabolite binding. The new shapes act to prevent the transcription of messenger RNA or translation of messenger RNA into protein. Although riboswitches have not yet been found in humans, Fedor believes this discovery is just a matter of time. "The great thing about the field of RNA is that we are always coming across unexpected findings," she said.

A guide star lets scientists see deep into human tissue

Sat, 12 Feb 2011 05:05:41 PDT

Astronomers have a neat trick they sometimes use to compensate for the turbulence of the atmosphere that blurs images made by ground-based telescopes. They create an artificial star called a guide star and use its twinkling to compensate for the atmospheric turbulence. Lihong Wang, PhD, the Gene K. Beare Distinguished Professor of Biomedical Engineering at Washington University in St. Louis, has invented a guide star for biomedical rather than celestial imaging, a breakthrough that promises game-changing improvements in biomedical imaging and light therapy.......> Full story

Fluorescent peptides help nerves glow in surgery

Mon, 07 Feb 2011 03:22:28 PDT

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered. The findings are published in the Feb. 6 advance online edition of the journal Nature Biotechnology. Nerve preservation is important in almost every kind of surgery, but it can be challenging, said Quyen T. Nguyen, MD, PhD, assistant professor of Head and Neck Surgery and the study's corresponding author. "For example, if the nerves are invaded by a tumor. Or, if surgery is required in the setting of trauma or infection, the affected nerves might not look as they normally would, or their location may be distorted." Nguyen and colleagues at the Moores Cancer Center developed and injected a systemic, fluorescently labeled peptide (a protein fragment consisting of amino acids) into mice. The peptide preferentially binds to peripheral nerve tissue, creating a distinct contrast (up to tenfold) from adjacent non-nerve tissues. The effect occurs within two hours and lasts for six to eight hours, with no observable effect upon the activity of the fluorescent nerves or behavior of the animals. "Of course, we have yet to test the peptide in patients, but we have shown that the fluorescent probe also labels nerves in human tissue samples," Nguyen said. Interestingly, fluorescence labeling occurs even in nerves that have been damaged or severed, provided they retain a blood supply. The discovery suggests fluorescence labeling might be a useful tool in future surgeries to repair injured nerves. Currently, the ability to avoid accidental damage to nerves during surgery depends primarily upon the skill of the surgeon, and electromyographic monitoring. This technique employs stimulating electrodes to identify motor nerves, but not sensory nerves such as the neurovascular bundle around the prostate gland, damage of which can lead to urinary incontinence and erectile dysfunction following prostate surgery. The new study complements earlier work in surgical molecular navigation by Nguyen and Roger Tsien, PhD, Howard Hughes Medical Institute investigator, UCSD professor of pharmacology, chemistry and biochemistry, a co-author of the paper and co-winner of the 2008 Nobel Prize in chemistry for his work on green fluorescent protein. In 2010, for example, the scientists and colleagues published papers describing the use of activated, fluorescent probes to tag cancer cells in mice. The ultimate goal of their work is to help surgeons identify and remove all malignant tissues by lighting up cancer cells, thus reducing the chance of recurrence and improving patient survival rates. "The analogy I use is that when construction workers are excavating, they need a map showing where the existing underground electrical cables are actually buried, not just old plans of questionable accuracy," said Tsien. "Likewise when surgeons are taking out tumors, they need a live map showing where the nerves are actually located, not just a static diagram of where they usually lie in the average patient." The researchers continue to refine their probes in animal models and prepare for eventual human clinical trials.